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ABSTRACT 
 
There are multiple binding domains on the promoter region of the peroxisome proliferator 
activator receptor gamma (γ) coactivator-1 α (PGC-1α) gene, including a trio of insulin 
responsive elements that are activated by the Forkhead box class-O (FoxO1) winged helix 
transcription factor, which is known to be regulated by acute transforming retrovirus thymoma 
(Akt). The first two experimental chapters (Chapters 2 and 3) of this thesis indicate that in 
skeletal muscle biopsy specimens from healthy humans and cultured human skeletal  myotubes, 
insulin phosphorylates Akt (Ser473) and FoxO1 (Thr24, Ser256), leading to reduced nuclear 
abundance of FoxO1 total protein. This is associated with an insulin-mediated repression of the 
mRNA expression of PGC-1α and downstream genes associated with oxidative phosphorylation. 
In contrast, in muscle taken from insulin resistant humans or in palmitate treated insulin resistant 
myotubes, neither Akt nor FoxO1 was phosphorylated by insulin resulting in a failure for nuclear 
exclusion of FoxO1 total protein, and an inability for insulin to  repress the mRNA expression of 
PGC-1α and downstream genes. To determine whether the regulation of FoxO1 was Akt 
dependent, the work that constitutes Chapter 4 describes experiments where Akt2 −/− and wild 
type mice were treated with or without insulin. Insulin phosphorylated Akt and FoxO1 (Thr24, 
Ser256) resulted in a reduced nuclear expression of FoxO1 total protein in wild type but not Akt2 
−/− skeletal muscle.  
 
The mammalian target of rapamycin (mTOR) is regulated by growth factors to promote protein 
synthesis. In mammalian skeletal muscle, the Forkhead-O1 transcription factor (FoxO1) 
promotes protein catabolism by activating ubiquitin-protein ligases. Using both C2C12 mouse 
myoblasts stably expressing FoxO1-ER fusion proteins that are rapidly activated by 4- OH 
 XXII
 
tamoxifen and transgenic mice that specifically overexpress constitutively active FoxO1 in 
skeletal muscle (FoxO++/+), Chapter 5 provides evidence that FoxO1 inhibits mTOR signaling 
and protein synthesis. Activation of constitutively active FoxO1 induced the expression of 
eukaryotic initiation factor 4E binding protein 1 (eIF4E-BP1) mRNA and protein, but reduced 
eIF4E-BP1 phosphorylation (Thr37/46).  The reduction in eIF4E-BP1 phosphorylation was 
associated with a reduction in the abundance of Raptor and mTOR, Raptor-associated mTOR, 
reduced phosphorylation of the downstream protein p70S6 kinase and attenuated protein 
synthesis. The FoxO++/+ mice, characterized by severe skeletal muscle atrophy, displayed 
increased nuclear FoxO1 abundance and eIF4E-BP1 protein expression which was associated 
with reduced eIF4E-BP1 phosphorylation, Raptor, and mTOR protein abundance. These results 
provide the first evidence that FoxO1 per se inhibits protein synthesis via increased expression of 
the translational protein eIF4E-BP1 and reduced signaling through mTOR/Raptor complexes.  
  
 
In conclusion, insulin decreases the expression of genes involved in oxidative metabolism in 
healthy but not insulin resistant muscle, due to a decrease in FoxO1 phosphorylation and nuclear 
exclusion secondary to reduced Akt activity. FoxO1 may be an important therapeutic target in 
human disease where catabolism of muscle is observed, as FoxO1 appears to inhibit protein 
synthesis and translation/initiation pathways. 
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 1
CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
 
 
 
Transcription factor regulation of gene expression 
 
Gene activation is a multi-step process involving a very large number of proteins functioning in 
discrete complexes (Spiegelman & Heirich 2004). Eukaryotic cells carry a monolithic proportion 
of genetic information. This information encodes in the range of 6000-100,000 proteins which 
are necessary to promote and perpetuate life and this situation is true from yeast to man. In order 
for the organism to propagate and thrive, its genome must also contain vast amounts of cis-
regulatory DNA that can respond to spatial and temporal patterns of gene expression initiated by 
upstream metabolic requirement, developmental programs and a plethora of external stimuli 
(Lemon & Tjiam 2001). To maintain regulation of these genetic adaptive responses, eukaryotes 
have organized co-linear DNA into discrete chromosomes each packaged into chromatin. 
Transcription factors can be thought of as biological molecular machines that navigate through 
chromatin to promote target gene expression. Transcription factors bind to DNA in a sequence 
specific manner and when bound they essentially mark a gene for activation or repression 
through the recruitment of co-activator or co-repressor proteins (Speigelman & Heirich 2004). 
 
 
FoxO transcription factors: identification of the Forkhead DNA binding 
domain 
 
Initial evidence for a new DNA-binding motif came when Hepatocyte Nuclear Factor-3 (HNF-3) 
α, β, and γ were found to share a novel, highly conserved DNA-binding region (Lai et al., 1990; 
Lai et al., 1991) with the nuclear protein product of the Drosophila homeotic fork head gene, 
 2
 
involved in the formation of terminal structures of the early fly embryo. The Drosophila 
Forkhead (Fkh) gene was reported to be essential for proper formation of terminal structures of 
the embryo (Weigel et al., 1989; Weigel & Jackel 1990). Mutations of the Fkh gene caused 
homeotic transformation of gut structures into head-derived elements. The nuclear localisation of 
Fkh in these early studies suggested that Fkh regulated the transcription of other subordinate 
genes (Weigel et al., 1989). 
 
Shortly after the initial description of Drosophila Forkhead, a small family of hepatocyte 
enriched DNA-binding transcription factors (Hepatocyte Nuclear Factor-3 [HNF-3]) were 
described in rodents (Lai et al., 1990). The DNA binding domain of the HNF factors encompass 
a region of about 110 amino acid residues. At the time of reporting, the DNA binding domain of 
HNF factors did not resemble any other known DNA binding motif (Lai et al., 1990). However, 
later studies employing amino acid sequence comparisons, noted a high degree of similarity 
between the DNA binding domains of Forkhead and HNF proteins (Weigel & Jackle 1990). As a 
result, this particular DNA binding domain sequence was termed the Forkhead/HNF-3 domain. 
The Forkhead/HNF-3 DNA binding domain was later reported to be present in many proteins 
from yeast to human suggesting conservation of this domain across species types (Lai et al., 
1993). This conserved region also known as the ‘winged helix’ domain is a variant of the helix-
turn-helix motif (Brennan 1993).  The structure of the fork head/HNF-3 domain was resolved via 
X-ray crystallography analysis on the complex of the fork head domain of HNF-3γ with its 
cognate DNA at resolution of 2.5 angstroms (Å), (Clark et al., 1993). The forkhead/HNF-3 or 
‘winged helix’ domain is responsible for DNA binding specificity and binds DNA as a monomer, 
with two loops or ‘wings’ on the C-terminal side of the helix-turn-helix (Anderson et al., 1998). 
The ‘winged helix’ domain flanks a core derived of α-helical and β-helical elements. This 
 3
 
structure represents a unit that cannot be split without losing DNA-binding properties as revealed 
by foot-printing and deletion studies (Lai et al., 1990, 1991; Kaufmann et al., 1994). 
 
Forkhead Box transcription factors: unified nomenclature for winged 
helix/Forkhead transcription factors 
Following the initial identification of the Forkhead domain and its sequence homology to HNF-3, 
researchers identified in excess of 100 members of the Forkhead gene family, again, spanning the 
spectrum of species from yeast to human (for review see Kaufamnn and Knockel 1996). The 
rapidly developing interest in the Forkhead DNA binding motif resulted in the significant 
accumulation of reported sequences by many different laboratories leading to the use of multiple 
names and classifications for proteins sharing the Forkhead DNA binding domain. Cleary, this 
rapidly developing interest in the Forkhead domain resulted in confusion when following the 
literature and impeded the ability to name newly characterized winged helix/Forkhead 
transcription factors. This problem was recognized at the first International Meeting on 
Forkhead/Winged Helix proteins held in La Jolla, California, in November 1998. As a result it 
was proposed that a standardized nomenclature be developed for these proteins. Fox (Forkhead 
box) was adopted as the unified symbol for all chordate winged helix/Forkhead transcription 
factors (Kaestner et al., 2000).  
 
Fox proteins were assigned to individual subclasses based on phylogenetic analysis (Kaestner et 
al., 2000). As described by Kaester et al., (2000) a letter designated subclasses, and within each 
subclass proteins were given an Arabic numeral. Thus, the name of any particular Fox protein is 
‘Fox, subclass N, member X, or for example FoxO1. It was deemed appropriate those 
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abbreviations for the chordate Fox proteins contain all uppercase letters for human (e.g. FOXO1), 
but only the first letter capitalized for those expressed in the mouse (e.g. Foxo1) and the first and 
subclass letters capitalized for all other chordates (e.g. FoxO1) Kaestner et al., (2000). For the 
purposes of clarity, the protein will herein be referred to as FoxO within this thesis. 
 
As noted by Barthel et al., (2005), several features distinguish FoxO proteins from other 
Forkhead transcription factors. FoxO proteins contain a unique insert of five amino acids within 
the region of the DNA binding domain that is directly involved in sequence specific interaction 
with DNA binding sites. Whereas consensus sequences for binding most Forkhead proteins 
include a highly conserved core sequence (AAACA), the sequences flanking this core vary. The 
consensus binding sequence for FoxO proteins [(T/C)(G/A)AAACAA] diverges from that of 
other Forkhead proteins, providing a mechanism by which FoxO proteins can preferentially bind 
with a distinct set of target sites in the genome (Barthel et al., 2005). 
 
FoxO transcription factors: conservation across species 
As already noted, the Forkhead DNA binding domain is present in many proteins spanning 
various species. This conservation can also be applied to the FoxO subclass of Forkhead proteins. 
For example, FoxO1 (the mammalian ortholog of Caenorhabditis elegans DAF-16) was 
originally identified as a result of chromosomal translocation, t (2; 13) (q35; q14) and t (1; 13) 
(p36; q14) between PAX3 and/or PAX7 and FoxO (at that time called Forkhead homolog of 
Rhabdomyosarcoma [FKHR]), resulting in alveolar rhabdomyosarcoma tumor development 
(Galili et al., 1993; Borkhart et al., 1997; Anderson et al., 1998). Furuyama et al., (2000) & 
Biggs et al., (2001) confirmed FoxO protein expression in the mouse and assessed tissue 
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expression patterns. Orthology between human FoxO isoforms and DAF-16 was later confirmed 
(Lee et al., 2001) in experiments in C. elegans showing that FoxO could partially replace DAF-
16 in the insulin signaling cascade, which is subsequently discussed. 
 
Regulation of FoxO transcriptional activity 
FoxO proteins have emerged as important downstream targets of insulin and growth factor action 
(Barthel et al., 2005), with numerous studies indicating that FoxO orthologs lie downstream of 
intracellular insulin signaling in Drosphophila (Junger et al., 2003; Kramer et al., 2003; Puig et 
al., 2003; Hwangbo et al., 2004), the nematode C. elegans (Ogg et al., 1997; Lee et al., 2003; 
Murphy et al., 2003) and the mouse (Futuyama et al., 2000; Biggs et al., 2001). FoxO 
transcription factors interact with insulin response sequences (IRSs) on target gene promoters 
(Unterman et al., 1994; O’Brien et al., 1990; Daitoku et al., 2004; Puigserver et al., 2003). It is 
noteworthy that FoxO proteins are most highly expressed in insulin sensitive tissues such as 
skeletal muscle, liver, and adipose tissue (Imae et al., 2003). Insulin/growth factor stimulation 
negatively regulates FoxO transcription factor mediated gene expression via activation of 
phosphatidylinositol 3-Kinase (PtdIns3-K; PI-3K) and subsequent phosphorylation and activation 
of Acute Transforming Retrovirus Thymoma (Akt). Thus, FoxO proteins are substrates of the 
serine/threonine kinase Akt, and as such have conserved Akt sensitive residues that are 
phosphorylated in response to insulin mediated Akt activation (Biggs et al., 1999; Brunet et al., 
1999; Guo et al., 1999; Kops et al., 1999; Nakae et al., 1999; Rena et al., 1999; Takaishi et al., 
1999; Tang et al., 1999; Zhang et al., 2002), resulting in prompt and sustained FoxO protein 
nucleic exclusion (cytosolic sequestration) and transcriptional depression of FoxO target genes 
(Rena et al., 2002).  The nucleic exclusion of FoxO proteins is mediated via a cytosolic protein 
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called 14-3-3 (Rena et al., 2001; Zhao et al 2004). Early studies suggested that phosphorylation 
of FoxO proteins resulted in 14-3-3 binding (Brunet et al., 1999) and moreover, the Serine 256 
residue/phosphorylation site on FoxO1 was shown to be critical for this binding (Rena et al., 
2001). These early studies suggest that 14-3-3 proteins were negative regulators of FoxO1 protein 
transcriptional activity. However, more recent work suggests this not to be the case, as it appears 
that some 14-3-3 proteins interact with FoxO proteins to promote lifespan extension. In C. 
elegans, two newly discovered 14-3-3 proteins (PAR-5 and FTT-2) described in three 
independent reports suggest that 14-3-3 proteins are required for Sir2.1 induced transcriptional 
activation of DAF-16 (the C. elegans orthologs of SIRT1 and FoxO1 respectively) and the 
interactions of these proteins positively increase life span (Berdichevesky et al., 2006; Wang et 
al., 2006; Li et al., 2007). Of interest, the work of Berdichevesky et al., (2006) showed that in 
response to heat stress, Sir 2.1 binds DAF-16 in a 14-3-3 dependant manner to promote lifespan 
extension, but in contrast, the stress imposed by low insulin-like signaling did not promote this 
association. Work to determine if these effects are conserved in humans is warranted. 
 
Whilst there is broad consensus that Akt-dependant phosphorylation is crucial to the regulation of 
FoxO function and transcriptional targeting, recent reports suggest that FoxO proteins are also the 
target of the Sir orthologs (SIRT), or Sirtuins (Motta et al., 2004; Brunet et al., 2004; Yang et al., 
2005; Kobayashi et al., 2005). These reports provide convincing evidence that FoxO is acetylated 
in response to cellular stress by the acetyltransferase activity of the nuclear hormone receptor co-
activators Cbp and p300. Expression of SIRT1 causes FoxO deacetylation, and this deacetylation 
promotes cellular survival under stress conditions and protects against apoptosis by dampening or 
fine-tuning FoxO transcriptional gene targeting. Interestingly, Matusuzaki et al., (2005) suggest 
that acetylation of FoxO leads to a decrease in its DNA binding affinity, and moreover, acetylated 
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FoxO proteins become more sensitive to Akt dependant phosphorylation. Taken together these 
data suggest that acetylation and phosphorylation cooperatively regulate the function of FoxO, 
whilst deacetylation regulates the contextual response/function of FoxO proteins. More work is 
required to elucidate the exact contextual cues and effects of FoxO acetylation/deacetylation. 
 
FoxO proteins in cellular differentiation 
As already eluded to, FoxO factors play a key role in transmitting insulin signaling downstream 
of acute transforming retrovirus thymoma (Akt). Given that FoxO proteins are ubiquitously 
expressed across tissues and species, the metabolic functions of FoxO proteins are somewhat 
predictable based on the work in C. elegans. Evidence in-vivo and from in-vitro cell culture  
experiments suggest an integrative role for FoxO proteins with regard to the processing of extra-
cellular cues and downstream transcriptional cascades that control differentiation. Nakae et al., 
(2003), reported that that FoxO1 is induced in the early stages of adipocyte differentiation but 
that its activation is delayed until the end of the clonal expansion phase (the end of the 
proliferative phase). Constitutively active FoxO1 (FoxO mutants refractory for Akt 
phosphorylation) prevents the differentiation of preadipocytes, while dominant-negative FoxO1 
restores adipocyte differentiation of fibroblasts from insulin receptor-deficient mice. Further, 
FoxO1 haploinsufficiency protects from diet-induced diabetes in mice (Altomonte et al., 2003). 
These authors proposed that FoxO1 plays an important role in the integration of hormone-
activated signaling pathways with the complex transcriptional cascade that promotes adipocyte 
differentiation (Nakae et al 2003). 
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Bois & Grosveld (2003) demonstrated that FoxO is localised in the cytoplasm of proliferating 
primary mouse myoblasts, yet translocates to the nucleus by a phosphorylation-independent 
pathway following serum starvation, a condition that induces myoblast differentiation. FoxO 
phosphorylation during terminal differentiation appears to down regulate its fusion activity, as a 
dominant-active, phosphorylation refractory FoxO mutant dramatically augments the rate and 
extent of myotube fusion. However, this FoxO mutant exerts its effects only after other events 
initiated the differentiation process. Conversely, enforced expression of a dominant-negative 
FoxO mutant blocks myotube formation whereas wild-type FoxO has no effect (Bois & Grosveld 
2003). These authors concluded that, in addition to the role of FoxO proteins in regulating cell 
cycle progress and apoptosis, FoxO controls the rate of myotube fusion during myogenic 
differentiation. 
 
Hribal et al., (2003) reported that a constitutively active FoxO1 mutant inhibits differentiation of  
C2C12 cells and prevents myotube differentiation induced by constitutively active Akt. In 
contrast, a transcriptional inactive mutant FoxO1 partially rescues inhibition of C2C12 
differentiation mediated by wortmannin (a chemical inhibitor of PI3-kinase immediately 
upstream of Akt), but not by rapamycin (a chemical inhibitor of mTOR), and is able to induce 
aggregation-independent myogenic conversion of teratocarcinoma cells. Inhibition of FoxO 
expression by siRNA resulted in more efficient differentiation, associated with increased myosin 
expression. These observations indicate that FoxO proteins are key effectors of Akt-dependent 
myogenesis. 
 
In terminally differentiated muscle cells, FoxO proteins work at the opposite end of the spectrum 
to induce genes associated with atrophy. Skeletal muscle atrophy is a debilitating response to 
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fasting, disuse, cancer, and other systemic diseases. In atrophying muscles, the ubiquitin ligase, 
atrogin-1 (MAFbx), is dramatically induced, and this response is necessary for rapid atrophy. 
Sandri et al., (2004) and Stitt et al., (2004) reported that in cultured myotubes undergoing 
atrophy, the activity of the PI3K/AKT pathway decreases, leading to activation of FoxO 
transcription factors and atrogin-1 induction. IGF-1 treatment or Akt over-expression inhibits 
FoxO and atrogin-1 expression. Moreover, constitutively active FoxO3 (Sandri et al., 2004) and 
FoxO1 (Stitt et al., 2004) act on the atrogin-1 promoter to cause atrogin-1 transcription and 
marked atrophy in both myotubes and muscle fibers. When FoxO activation was blocked by a 
dominant-negative construct in myotubes, or by siRNA in mouse muscles in-vivo, atrogin-1 
induction during starvation and atrophy of myotubes induced by glucocorticoids was prevented 
(Sandri et al., 2004; Stitt et al., 2004). Thus, FoxO proteins play a critical role in the development 
of muscle atrophy, and inhibition of these proteins appears to be an attractive approach for 
alleviating muscle wasting pathologies. 
 
FoxO proteins role in cell cycle arrest 
In cells undergoing proliferation, the main effect of the expression of active forms of FoxO 
family members is to promote cell cycle arrest at the G1/S boundary (Medema et al., 2000). 
Target genes that mediate FoxO-induced cell cycle arrest are the Cdk inhibitor p27KIP1 
(Medema et al., 2000) and the Rb family member p130 (Kops et al., 2002b). FoxO factors’ 
ability to induce G1 arrest is diminished in p27/ p130-deficient fibroblasts (Kops et al., 2002b), 
suggesting that p27 and p130 are both critical to mediate FoxO-dependent G1 arrest. In the 
presence of Transforming Growth Factor-Beta (TGF-β), FoxO factors also bind to the promoter 
of p21, a cell cycle inhibitor, and induce cell cycle arrest at the G1/S transition (Seoane et al., 
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2004). Interestingly, FoxO factors can also promote cell cycle arrest by repressing the expression 
of cyclin D1 and D2, two cell cycle positive regulators (Ramaswamy et al., 2002; Schmidt et al., 
2002). Thus, FoxO factors play a major role in G1 arrest by both up regulating cell cycle 
inhibitors (p21 and p27) and by repressing cell cycle activators (cyclin D1/D2). Akt promotes 
cellular proliferation by sequestering FoxO transcription factors in the cytoplasm and preventing 
them from inducing a G1 arrest. FoxO factors also play a role at other cell cycle checkpoints. 
Cells in which FoxO3 is activated in the S phase display a delay in their progression through the 
G2 phase of the cell cycle (Tran et al., 2002). Micro array analysis led to the identification of 
several FoxO3 target genes that may mediate FoxO's effect at the G2/M boundary, such as cyclin 
G2 and growth arrest and DNA damage-inducible protein 45 (GADD45) (Furukawa-Hibi et al., 
2002; Tran et al., 2002). Thus, FoxO factors mediate cell cycle arrest at the G1/S and G2/M 
transitions, two checkpoints that are critical in the cellular response to stress. FoxO-induced cell 
cycle arrest may allow time for repair of damaged DNA and for detoxification of cells. 
Consistent with FoxO factors’ role in promoting cell cycle arrest at the G1/S and G2/M 
boundaries, the expression of active forms of FoxO proteins up regulates several genes involved 
in DNA repair (Ramaswamy et al., 2002; Tran et al., 2002). GADD45 may mediate part of 
FoxO3-induced DNA repair since FoxO3- induced DNA repair is diminished in GADD45-
deficient fibroblasts (Tran et al., 2002). In addition, FoxO proteins have been reported to allow 
detoxification of reactive oxygen species (ROS) by up regulating the free radical scavenging 
enzymes, including Manganese Superoxide Dismutase (MnSOD) and catalase (Kops et al., 
2002a; Nemoto and Finkel, 2002; Ramaswamy et al., 2002; Tran et al., 2002). Thus, FoxO 
transcription factors control two aspects of the cellular resistance to stress: repair of the damage 
caused by ROS and removal of ROS byproducts. 
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FoxO proteins: role in metabolism 
Aspects of FoxO’s role in metabolism and metabolic gene expression in muscle constitute a 
significant part of this thesis and as such are reviewed in later chapters. Two interesting 
publications detailing these effects in the liver provided the rationale for some of the work in this 
thesis. 
 
Peroxisome proliferator-activated receptor-gamma coactivator-1 alpha (PGC-1α) plays a major 
role in mediating hepatic gluconeogenesis in response to starvation, during which PGC-1α is 
induced by the cyclic AMP response element binding protein. Although it is observed that insulin 
counteracts PGC-1α transcription, the mechanism by which insulin suppresses the transcription 
of PGC-1α was unclear. Daitoku et al., (2003) showed that Forkhead transcription factor FoxO1 
contributes to mediating the effects of insulin on PGC-1α promoter activity. Reporter assays 
demonstrated that insulin suppresses the basal PGC-1α promoter activity and that co-expression 
of Akt mimicked the effect of insulin in HepG2 cells. Insulin response sequences (IRSs) are 
addressed in the PGC-1 promoter as the direct target for FoxO1 in-vivo. Co-expression of FoxO1 
stimulates the PGC-1α promoter activity via interaction with the IRSs, while co-expression of 
FoxO (3A), in which the three putative Akt sites in FoxO1 are mutated, mainly abolishes the 
suppressive effect of Akt (Daitoku et al., 2003). Whereas deletion of the insulin responsive 
motifs prevents the promoter stimulation by FoxO, that activity is still partially inhibited by 
insulin. These results indicate that signaling via Akt to FoxO can partly account for the effect of 
insulin to regulate the PGC-1α promoter activity via the IRSs. Puigserver et al., (2003) 
concluded that hepatic gluconeogenesis is absolutely required for survival during prolonged 
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fasting or starvation, but is inappropriately activated in type 2 diabetes mellitus. Glucocorticoids 
and glucagon have strong gluconeogenic actions on the liver. In contrast, insulin suppresses 
hepatic gluconeogenesis (Puigserver et al., 2003; Daitoku et al., 2003). Two components known 
to have important physiological roles in this process are FoxO1 and PGC-1α, but whether these 
factors collaborate in the regulation of hepatic gluconeogenesis was, until recently, unclear. 
Using wild type and mutant alleles of FoxO1, Puigserver et al., (2003) demonstrated that PGC-
1α binds and co-activates FoxO1 in a manner inhibited by Akt-mediated phosphorylation. 
Furthermore, FoxO1 function was required for the robust activation of gluconeogenic gene 
expression in hepatic cells and in mouse liver by PGC-1α (Puigserver et al., 2003; Daitoku et al., 
2003). Insulin suppresses gluconeogenesis stimulated by PGC-1α but co-expression of a mutant 
allele of FoxO1 insensitive to insulin completely reverses this suppression in hepatocytes or 
transgenic mice. Puigserver et al., (2003), concluded that FoxO1 and PGC-1α interact in the 
execution of a program of powerful, insulin-regulated gluconeogenesis. 
 
Interestingly, Frescas (et al., 2005) published data relating to nucleic trapping of FoxO in 
hepatocytes under conditions associated with those seen in Type 2 diabetes. This trapping 
exacerbated FoxO driven gluconeogenic gene expression. This recent work extended that of 
Daitoku et al., (2003) and Puigserver et al., (2003) by showing that either Sirtuin activation or 
hydrogen peroxide treatment overrides the phosphorylation-dependent nuclear exclusion of 
FoxO1 caused by growth factors and leads to nuclear translocation of FoxO1 in hepatocytes. 
Kinetic measurements of nuclear fluorescence recovery after photo-bleaching showed that FoxO1 
was readily diffusible within the nucleus under normal conditions but became restricted within a 
nuclear sub-domain after treatment with the prototypical Sirtuin agonist resveratrol or oxidative 
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stress. Expression of FoxO1 target genes was increased accordingly, leading to activation of 
gluconeogenesis and increased glucose release from hepatocytes (Frescas et al., 2005). 
 
Imae et al., (2003) investigated if the mRNA levels of FoxO isoforms in rat liver respond to the 
stimuli of several nutritional and hormonal factors. Imposed fasting for 48 h significantly 
elevated mRNA levels of FoxO1 (1.5-fold), FoxO3 (1.4-fold), and FoxO4 (1.6-fold). Re-feeding 
for 3 h recovered the induced mRNA levels of FoxO1 and FoxO3 to control levels, but did not 
affect the mRNA levels of FoxO4. FoxO1 and FoxO4 mRNA levels were proved to be highly 
reflective of their protein levels measured by western immunoblotting. Of the three FoxO genes, 
FoxO4 alone showed altered levels of mRNA (a 1.5-fold increase) in response to a protein-free 
diet. Streptozotocin-induced diabetes for 28 days decreased hepatic mRNA levels of FoxO1 and 
FoxO3 and increased the level of FoxO4 mRNA, but short-term (7 days) diabetes induction had 
fewer effects on the expression of these genes. Insulin replacement partially restored the FoxO1 
and FoxO4 mRNA levels, but had no effect on the FoxO3 mRNA level. Dexamethasone, a 
synthetic glucocorticoid, administered daily for one week increased the mRNA levels of FoxO1 
(1.8-fold) and FoxO3 (2.4-fold) (Imae et al., 2003). These results showed that the FoxO genes 
respond differently to nutritional and hormonal factors, suggesting a mechanism for the 
regulation of FoxO-dependent gene expression by these factors. Moreover, changes of FoxO1 
and FoxO4 in the nucleus in response to fasting also suggest that the regulation of 
nucleus/cytoplasm translocation actually functions in-vivo. 
 
Bastie et al., (2005), investigated the role of FoxO1 in the regulation of fatty acid (FA) 
metabolism in muscle cells. C2C12 cells expressing an inducible construct with either wild type 
FoxO1 or a mutant form refractory for the activity of Akt were generated. FoxO1 activation after 
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myotube formation altered the expression of several genes of Fatty acid metabolism. Acyl-CoA 
oxidase and peroxisome proliferator-activated receptor delta mRNA levels increased 2.2-fold and 
1.4-fold, respectively, whereas mRNA for acetyl-CoA carboxylase decreased by 50%. Membrane 
uptake of oleate increased 3-fold, and oleate oxidation increased 2-fold. Cellular triglyceride 
content was also increased. The enhanced FA utilisation induced by FoxO1 was mediated by a 
seven fold increase in plasma membrane level of the fatty acid translocase FAT/CD36 and 
eliminated by cell treatment with the CD36 inhibitor sulfo-N-succinimidyl-oleate. Bastie et al., 
(2005) concluded that in C2C12 cells, FoxO1 effects on FA uptake exceeded those on oxidation, 
resulting in net triglyceride accumulation and that these effects were mediated, at least in part, by 
membrane enrichment in CD36. These data suggest that FoxO1 contributes to preparing the 
muscle cell for the increased reliance on FA metabolism that is characteristic of fasting. 
Dysregulation of FoxO1 in muscle could therefore contribute to insulin resistance due to 
dysregulated fatty acid uptake leading to intramuscular lipid accumulation, a known primary 
cause of insulin resistance (Pan et al., 1997). 
 
To better understand the role of FoxO proteins in the metabolic parameters in the liver, Zhang et 
al, (2006) created transgenic mice expressing constitutively active FoxO1 in the liver using the 
alpha1-antitrypsin promoter. Fasting glucose levels were increased, and glucose tolerance was 
impaired in transgenic versus wild type mice. Interestingly, fasting triglyceride and cholesterol 
levels were reduced despite hyperinsulinaemia, and post-prandial (post meal/feeding) changes in 
triglyceride levels were markedly suppressed in transgenic versus wild-type mice. Activation of 
pro-lipogenic signaling pathways (atypical protein kinase C and protein kinase B) and the ability 
to suppress beta-hydroxybutyrate levels were not impaired in the transgenic mice. In contrast, de 
novo lipogenesis measured with 3H2O was suppressed by approximately 70% in the liver of the 
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transgenic mice after re-feeding. Gene-array studies revealed that the expression of genes 
involved in gluconeogenesis, glycerol transport, and amino acid catabolism were increased, 
whereas genes involved in glucose utilization via glycolysis, the pentose phosphate shunt, 
lipogenesis, and sterol synthesis pathways were suppressed in transgenic mice compared to wild-
type controls (Zhang et al., 2006). Studies utilising adenoviral vectors in isolated hepatocytes 
confirm that FoxO1 stimulates expression of gluconeogenic genes and suppresses expression of 
genes involved in glycolysis, the shunt pathway, and lipogenesis, including glucokinase and 
SREBP-1c (Zhang et al., 2006). Together, these results indicate that FoxO proteins promote 
hepatic glucose production through multiple mechanisms and contribute to the regulation of other 
metabolic pathways important in the adaptation to fasting and feeding in the liver, including 
glycolysis, the pentose phosphate shunt, and lipogenic and sterol synthetic pathways. These 
metabolic effects of FoxO proteins have been comparatively less well characterised in skeletal 
muscle. 
 
FoxO’s regulation of cell growth 
Studies conducted in lower order organisms (Drosophila & C. elegans) suggest that FoxO 
proteins may also play role in cell growth/size regulation via their interaction with a common set 
of effectors in the mammalian target of rapamycin mTOR signaling pathway. The mTOR 
pathway is emerging as a major contributor in the regulation of cellular growth. mTOR proteins 
are protein kinases that were first identified in Saccharomyces cerecisiae through mutants that 
confer resistance to growth inhibition induced by the immunosuppressive macrolide rapamycin 
(Kunz et al.,1993). Interestingly, in response to growth factor (e.g. insulin) activation, Regulatory 
Associated Protein of mTOR (Raptor), a 150-kD polypeptide identified by Kim et al. (2002), 
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forms a complex with mTOR and phosphorylates eukaryotic Initiation Factor 4- Binding Protein 
1 (eIF4E-BP1) (Hara et al., 2002). De-phosphorylation of eIF4E-BP1 is a limiting factor in 
protein synthesis, as a result of increased association with eIF4E. Raptor is indispensable for 
TOR signaling in-vivo (Kim et al., 2002), and is absolutely required for the mTOR-catalysed 
phosphorylation of eIF4E-BP1 in-vitro (Hara et al., 2002; Nojima et al., 2003).  
 
Jia et al. (2004) conducted studies in C. elegans to investigate if DAF 16 imposed any 
transcriptional regulation on DAF 15 (C. elegans orthologs of mammalian FoxO and Raptor 
respectively). Using mutants where DAF 2 (C. elegans insulin receptor orthologs) are active or 
inactive, rendering DAF 16 (FoxO) inactive or active respectively, these authors found that in the 
active state, DAF 16 (FoxO) inhibited DAF 15 (Raptor) expression suggesting that FoxO proteins 
may have the potential to act as transcriptional repressors of Raptor expression. 
 
Junger et al. (2003) investigated dFOXO (Drosophila FoxO) transcriptional targets. These 
experiments were performed within a context of cellular stresses, such as nutrient deprivation or 
increased levels of reactive oxygen species. These authors provide evidence that during cellular 
stress, dFOXO is active and promotes growth inhibition via the promotion of increased 
expression of d4E-BP1 (the Drosophila ortholog of mammalian eIF4E-BP1). The finding that 
d4E-BP1 is a bone fide transcriptional target of dFOXO was confirmed by Teleman et al. (2005a) 
utilising oxidative stress induction and starvation protocols. This study investigated dFOXO 
mediated induction of d4E-BP in a similar contextual model to that of Junger et al. (2003) but 
related the 4E-BP induction back to metabolism. In this regard, Teleman et al. (2005a) reported 
that an increased storage of lipid was seen during starvation concomitantly with induction of 4E-
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BP, and moreover this induction of lipid storage and 4E-BP was dFOXO dependant. These 
authors subsequently showed that a molecule called MELTED binds dFOXO in response to 
growth factor stimulation and subsequently recruits FOXO to the inner apical cell membrane 
thereby inhibiting dFOXO transcriptional activity. In MELTED mutant flies (flies with genetic 
ablation of the MELTED gene) dFOXO retained its transcriptional activity with regard to the 
promotion of d4E-BP1 (Teleman et al., 2005b).  
 
Taken together, these data suggest that FoxO proteins regulate components or effectors of cell 
growth and inducers of translation initiation in response to environmental cues. These 
observations raise the possibility that FoxO1 may not only contribute towards catabolic processes 
via activation of ubiquitin ligase’s (as discussed earlier in this chapter), but also via repression of 
anabolic pathways. 
 
Summary 
In summary, FoxO proteins are conserved across species and tissue types and their transcriptional 
activity is dictated via growth factor mediated phosphorylation and subsequent nucleic exclusion. 
There is evidence to suggest that acetylation and deacetylation fine tune the phosphorylation 
dependant nucleic exclusion and in the case of deacetylation. This fine-tuning  
represents a means of mediating target gene expression according to specific stimuli. FoxO 
proteins have a specific role in the differentiation of various cell types, and once the 
differentiation process has concluded, FoxO proteins subsequently regulate cellular size. In 
proliferating cells the main effect of forced activation or constitutively active forms of FoxO is to 
promote cell cycle arrest at the G1/S boundary, whilst also up regulating genes associated with 
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DNA repair and detoxification. FoxO regulates metabolic profiling in the liver via the targeting 
of a repertoire of genes associated with gluconeogenesis, and this targeting appears to be 
increased insulin resistant models, thereby exacerbating the diabetic phenotype. It would appear 
that the overall role of FoxO in metabolic profiling in the liver is to promote hepatic glucose 
output, whilst mediating other metabolic pathways pertinent to adaptation involved in fasting to 
feeding.  
In muscle cells, data suggest that FoxO proteins prepare the muscle cell for an increased reliance 
on fatty acid metabolism, a situation that is characteristic of fasting, and as such could contribute 
towards intramuscular lipid accumulation and insulin resistance by maintaining fatty acid uptake. 
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Figure 1.1 Model of FoxO gene expression showing interplay between vaious FoxO 
target genes. 
 
During times of intracellular stress (e.g starvation, osmotic, ultra violet), FoxO transcription 
factors appear to induce a program of gene expression specific to the contextual stimuli. In 
this regard, low level stress promotes the induction of genes associated with oxidative stress 
protection and genes associated with metabolic adaptation.  As the insulting stimuli persists  
(moves towards a chronic state) or intensifies, FoxO induces genes associated with cell cycle 
arrest (with concomitant changes in metabolic gene expression)  thus inhibiting propagation 
and proliferation of cells containing damaged DNA. If the insult becomes chonic, FoxO 
promotes a program of apoptosis or growth restriction depending upon tissue specificity. 
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Aims of thesis 
 
The primary aim of this thesis was to investigate the role of FoxO1 in skeletal muscle, with 
particular emphasis on FoxO1’s role in the promotion of metabolic and growth regulatory gene 
expression. The FoxO family of transcription factors is relatively newly described. The research 
effort identified the winged-helix DNA binding domain associated with FoxO transcription 
factors some 13 years ago and since then the literature on these diverse transcription factors has 
grown enormously. 
 
Work conducted in hepatocytes (published by other authors) suggested that FoxO1 targeted genes 
that exacerbate the insulin resistant state via the induction of a program of gluconeogenesis. 
Other work suggested that the basal expression of PGC-1α, a FoxO1 target, was reduced in 
insulin resistant muscle tissue. We hypothesized that FoxO1 transcriptional activity would be 
increased in the muscle of insulin resistant subjects.  The work that constitutes Chapters 2, 3, and 
4 of this thesis support the hypothesis and suggest that the regulation of FoxO1 transcriptional 
activity by insulin, in muscle tissue, is perturbed in the insulin resistant state. The observations 
reported in this thesis represent an important extension of the previously published work 
 
After establishing that FoxO1 regulation was perturbed in insulin resistance in-vivo and in 
experimentally induced insulin resistance in-vitro, it seemed reasonable to investigate how 
FoxO1 regulated intrinsic genes and proteins associated with the processing and expression of 
components of the growth regulatory pathways present in muscle cells (Chapter 5). The rationale 
for these later studies was related to the observation that insulin resistance appears to induce 
metabolic and size changes in muscle, and yet total dissemination of the tissue is not realised. It 
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was deemed important to investigate how FoxO1 might slow or reduce growth regulatory 
pathways in order that tissue maintains structural probity albeit with a reduced function. These 
later studies elucidated a role for FoxO1 in regulation of components that prime for the induction 
of translation and initiation of protein synthesis from messenger RNA (mRNA) in muscle tissue.  
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CHAPTER 2 
INTRODUCTION 
 
Evidence is emerging linking muscle insulin resistance with mitochondrial dysfunction (Peterson 
et al., 2003), and it has recently been reported that genes associated with mitochondrial function 
are down regulated in patients with Type 2 diabetes (Patti et al., 2003). Co-activators are 
important intracellular molecules, and although they do not directly bind to DNA, they can 
modulate gene expression through specific protein-protein interactions (Ichida et al., 2003). One 
such co-activator receiving much attention due to its hypothesised role in Type 2 diabetes (Attie 
and Kendziorski 2003) is the peroxisome proliferator-activated receptor γ coactivator-1α (PGC-
1α), which was originally identified as a co-activator of PPAR-γ in-vitro (Puigserver et al., 
1998). Recent studies have demonstrated a down regulation of PGC-1α mRNA and associated 
genes in adipose tissue (Semple et al., 2004; Hammarstedt et al., 2003) and skeletal muscle (Patti 
et al., 2003; Mootha et al., 2003) of insulin resistant humans, although this is not always seen 
(Hammarstedt et al., 2003). It is suggested that PGC-1α is the hierarchical regulator of the 
oxidative phosphorylation (OxPhos) genes; Nuclear Respiratory Factor-1 (NRF-1) and 
mitochondrial transcription factor A (tFAM) which constitute a family of genes responsible for 
mitochondrial biogenesis and slow twitch (oxidative) muscle fibre expression (Puigserver & 
Spiegelman 2003). PGC-1α exerts this regulatory role via association with NRF-1, to control 
expression of tFAM (Lin et al., 2002), the signal through which the nucleus regulates 
mitochondrial DNA transcription and replication (Gordon et al., 2003). Thus, it is not surprising 
that suppression of PGC-1α in skeletal muscle could contribute towards insulin resistance via 
reduced mitochondrial size and number.  
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The regulation of PGC-1α gene transcription is complex. It is known that calcium (Ca2+) 
activates calcineurin (CnA) and calmodulin kinases (CaMK). CnA activates Nuclear Factor of 
Activated T cells (NFAT) (Shulz & Yutzey 2004) which works in a combinatorial fashion with 
myocyte enhancer factor 2 (MEF2), (Wu et al., 2001) to regulate oxidative fiber development. 
MEF2 acts as transcription factor for PGC-1α in a CaMK dependant manner (Czubryt et al., 
2003) where CaMK phosphorylates and inhibits DNA binding of the class II histone deacetylases 
(HDAC). The class II HDAC’s are suggested to negatively regulate PGC-1α via inhibition of 
MEF2 binding on the PGC-1α promoter (Czubryt et al., 2003). Taken together these previous 
studies suggest that MEF2 links the CaMK and calcineurin pathways to PGC-1α transcription. 
Increased adrenaline can also activate cyclic AMP (cAMP) to phosphorylate a cAMP responsive 
element-binding protein (CREB), which activates CRE on PGC-1α (Daitoku et al., 2003). Hence, 
it is likely that in patients with type 2 diabetes, physical inactivity leads to reduced NFAT, MEF2 
and CREB binding to the PGC-1α promoter, thereby resulting in the decreased PGC-1α mRNA 
and downstream genes observed basally in the skeletal muscle of these patients (Patti et al., 2003; 
Mootha et al., 2003).  
 
There is also a trio of insulin responsive elements on the promoter region of the PGC-1α gene 
that are activated by FoxO1 (Puigserver et al., 2003; Daitoku et al., 2003). FoxO1 is expressed in 
insulin sensitive tissues such as skeletal muscle, liver, and adipose tissue (Crunkhorn et al., 
2004). In these tissues, FoxO factors play a key role in transmitting insulin signaling downstream 
of Akt, where insulin negatively regulates FoxO trans-activation in such a way that upon insulin 
stimulation, Akt phosphorylates FoxO proteins resulting in their cytosolic sequestration (nucleic 
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exclusion) (Puigserver et al., 2003; Imae et al., 2003; Rena et al., 1999) and subsequent 
proteosomal degradation (Matsuzaki et al 2003). In hepatocytes, phosphorylation of FoxO1, by 
Akt in response to insulin, abolishes FoxO1 binding to PGC-1α and these events reduce the 
expression of the gluconeogenic genes PEPCK and G-6-Pase (Puigserver et al., 2003). Daitoku et 
al. (15) recently reported that, in Hep G2 cells, insulin suppresses basal PGC-1α promoter 
activity and co-expression of constitutively active Akt mimics the effect of insulin. Moreover, co-
expression of FoxO1 stimulated the PGC-1α promoter activity via interaction with PGC-1α’s 
insulin response sequences (IRSs), whilst co-expression of FoxO1 mutant, where the three 
putative Akt phosphorylation sites in FoxO1 are non-functioning, abolished the suppressive 
effects of Akt on FoxO1 trans-activation of the PGC-1α promoter (Puigserver et al., 2003; 
Daitoku et al., 2003).  
 
It is well known that, in healthy skeletal muscle, insulin phosphorylates Akt, a process that can be 
impaired in the skeletal muscle of patients with Type 2 diabetes (Zierath et al., 1994). Somewhat 
surprisingly, no previous studies have examined the Akt mediated regulation of FoxO1 and PGC-
1α by insulin in skeletal muscle, but this is warranted given the recent importance of PGC-1α in 
the aetiology of insulin resistance and the fact that skeletal muscle accounts for >80% of insulin 
stimulated glucose disposal. The work constituting this chapter examined the effect of insulin on 
Akt and FoxO1 phosphorylation and PGC-1α mRNA expression in skeletal muscle from healthy 
and insulin resistant humans.  
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Figure 2.1 Control of PGC1-α transcriptional regulation in 
skeletal muscle. 
 
Three promoter regions are calcium (Ca2+) and protein kinase A (PKA) responsive. 
Upon contraction Ca2+ activates calcineurin (CnA) and calmodulin kinases (CaMK). 
CnA activates nuclear factor of activated T cells (NFAT) and myocyte enhancer 
factor 2 (MEF2), which act as transcription factors for PGC1-α. CaMK 
phosphorylates histone deacetylases (HDAC), which inhibit the MEF2-responsive 
element on PGC1-α. Increased adrenaline can activate cyclic AMP (cAMP) to 
phosphorylate cAMP-responsive element binding protein (CREB), which activates 
CRE on PGC1-α There is also trio of insulin-responsive elements on the promoter 
region. These are activated by the forkhead box class-O (FoxO1) winged helix 
transcription factor, previously known as forkhead homologue of rhabdomyosarcoma 
(FKHR). When insulin binds to its receptor and activates PI3K, resulting in Akt 
phosphorylation, FoxO1 is phosphorylated and excluded from the nucleus. This 
process is impaired in insulin resistance.  
 
As adapted from Southgate et al., (2005). 
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METHODS 
 
Subjects 
A total of 16 volunteers (7 patients with type 2 diabetes [TYPE 2] and nine healthy but sedentary 
age-matched control subjects [CON]) participated in this investigation that was approved by the 
Human Ethics Committee of RMIT University. Normal glucose tolerance was confirmed in the 
control group [CON] by an oral glucose tolerance test (OGTT; 75 g glucose). TYPE 2 subjects 
had a mean time of 4 ± 1 yr since diagnosis of disease (range 6 months to 10 yr). All participants 
had maintained a constant body mass in the 6 months prior to the experiment and each was 
instructed to abstain from any form of vigorous physical activity for 36 h prior to the 
hyperinsulinaemia euglycaemic clamp experiment and to maintain their habitual diet. The 
subjects reported to the laboratory for this experiment following a 12-14 h overnight fast. 
 
Experimental protocol 
Patients arrived and rested supine for approximately 30 min. An anticubital vein (infusion of 
glucose and insulin), and a dorsal hand vein (blood sampling) were subsequently cannulated. The 
hand was continuously heated in order to sample arterialised blood. After collection of baseline 
blood samples, a percutaneous biopsy from the vastus lateralis muscle was obtained. After 
resting for 5 min a primed (9 mU·kg-1) continuous (40 mU·m-2·min-1) infusion of insulin  
(Actrapid, Novo Nordisk, Australia) was commenced and a variable rate infusion of 20% glucose 
was used to maintain euglycaemia (5 mmol/L-1) for 120 min. The blood glucose concentration in 
TYPE 2 was allowed to decrease during the insulin infusion to 5 mmol.L-1 and then maintained at 
this concentration for the remainder of the clamp. A second muscle biopsy was obtained at the 
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conclusion of the clamp. To prevent a decrease in plasma potassium concentration during the 
clamp, 30 mmol KCl (Slow-K; Novartis, Australia) was administered orally. 
 
RNA extraction  
Muscle tissue was homogenised and extracted for total RNA using the acid guanidium 
thiocyanatephenol-chloroform extraction method (Chomczynski et al., 1987) and modified 
according to methods described elsewhere (Febbraio & Koukoulas 2000).  RNA samples were 
reverse transcribed using a thermal cycler (Perkin Elmer GeneAmp PCR 2400 Thermal Cycler, 
Rowville, Victoria, Australia) with TaqMan Reverse Transcription Reagents (Applied 
Biosystems, Foster City CA, USA) in 40 µl reaction mixtures containing 1 x TaqMan RT Buffer, 
5.5 mM MgCl2, 500 µM 2’-deoxynucleoside 5’-triphosphate, 2.5 µM random hexamers, 0.4U µl-
1 RNase inhibitor, 1.25 U/µl-1 multiscribe reverse transcriptase. Control (reverse transcriptase 
negative) samples were also made and included in all future PCR analyses to check for genomic 
DNA contamination. 
 
Real-Time-Polymerase-Chain-Reaction analysis 
Real-time PCR was employed to quantify the genes of interest. All reactions were performed 
according to the multiplex comparative critical threshold (CT) method. This method allows for 
the detection of the reference gene (ribosomal 18S) and the gene of interest in the same well or 
tube. Preliminary experiments were performed to determine the efficiency of amplification of 
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18S and the gene of interest. PCR reactions were performed (in duplicate) in 96 well plates on a 
BioRad i-CYCLER iQ RealTime-PCR Detection System in 25 µl reaction volumes consisting of: 
BioRad iQ™ Supermix PCR mix (2 x; BioRad), Applied Biosystems Pre-Developed Assay 
Reagent for 18S (Applied Biosystems, Foster City CA, USA), the forward and reverse primers 
and probes of the genes of interest (see Table 1 for sequences, Appendix 1) and sterile H2O. 
Human probe and primers were designed (Primer Express version 1.0 Applied Biosystems, 
Foster City CA) from the human gene sequence accessed from Gen-Bank/EMBL.  The specific 
probe/primer sequences are reported in Table 1 (Appendix 1). 
 
Western blot analyses   
Muscle tissue was homogenised (Polytron; Brinkman Instruments, Westbury, NY, USA) in ice-
cold buffer containing 50 mM HEPES, 150 mM NaCl, 10 mM NaF, 1 mM Na3VO4, 5 mM 
EDTA, 0.5% Triton X-100, 10% glycerol (v: v), 2 mg.mL-1 leupeptin, 100 mg.mL-1 PMSF, and 2 
mg.mL-1 aprotinin. Homogenates were spun in order to pellet cellular debris at 16,000 g for 60 
min at 4oC and the supernatant was removed and rapidly frozen in liquid nitrogen.  Protein 
concentration of the muscle lysates was subsequently determined (Pierce, Rockford, IL, USA).  
Muscle lysates were solubilised in Laemmeli sample buffer and boiled for 5 min, resolved by 
SDS-PAGE on 10% polyacrylamide gels, transferred to a nitrocellulose membrane, blocked with 
3% BSA and immunoblotted overnight with total-Akt, phospho-Akt (Ser473), total-FoxO1, 
phospho-FoxO1 (Ser256) or phospho-FoxO1 (Thr24) antibodies (1:1000; Cell Signaling, Beverley, 
MA). After incubation with horseradish peroxidase-conjugated secondary antibody (1:2000; 
Amersham Biosciences, Castle Hill, NSW, Australia), the immunoreactive proteins were detected 
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with enhanced chemiluminescence (Perkin Elmer, Rowville, Victoria, Australia) and quantified 
by densitometry. All phospho-proteins were expressed as a ratio of phospho-to-total protein. 
 
 
Maximal enzyme activities  
Citrate synthase (CS) and β-hydroxyacyl CoA dehydrogenase (β-HAD) activities were analyzed 
by homogenising 5-10 mg of skeletal muscle in 1:50 dilution (w/v) of a 175 mM potassium 
buffer solution and measuring the disappearance of NADH spectrophotometrically at a constant 
temperature of 25oC according to the methods of Lowry and Passonneau (1972). 
 
Statistical analysis 
Data are presented as mean ± Standard Error of Mean (SEM).  Statistical analysis consisted of a 
paired t-test for figure 2.2, one-way ANOVA for figure 2.3 and two-way ANOVA (condition x 
treatment) for all other figures. Significance was accepted if P ≤0.05. Where analyses revealed a 
significant interaction, a Newman Keuls post-hoc test was used to locate specific differences. All 
statistical analyses were performed with the application of Statistica for Windows (Statsoft, 
StatisticaTulsa OK). 
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RESULTS 
Subject characteristics 
The subject characteristics are presented in Table 2 (Appendix 1). As expected fasting blood 
glucose, insulin, FFA and HbA1c were all higher (P<0.05) in Type 2 diabetic (TYPE 2) 
participants when compared with healthy control (CON) participants. Neither blood glucose nor 
plasma insulin levels during the clamp differed when comparing TYPE 2 with CON. 
 
Glucose infusion rate 
As expected, glucose infusion rate (GIR) was lower (P<0.05) in TYPE 2 compared with CON 
averaging 2.0 ± 0.1 and 7.9 ± 0.9 mg.kg-1.min-1 respectively (Figure. 2.2). 
 
Basal mRNA expression 
The basal mRNA expression of PGC-1α and downstream metabolic and mitochondrial genes are 
presented in Figure 2.3. The mRNA expression in the muscle biopsy specimens from the TYPE 2 
cohort was expressed relative to CON (Con = 1). The mRNA expression of PGC-1α, COX4, 
tFAM, and NRF-1 were all lower (P<0.01) in TYPE 2 compared with CON. Although not 
significant, the expression of FoxO1 (P=0.10) and PSARL (P=0.16) tended to be lower in TYPE 
2 compared with CON. 
 
Mitochondrial enzyme activity 
CS maximal activity was lower (P<0.05) in TYPE 2 compared with CON averaging 3.6 ± 0.3 and 
5.5 ± 0.4 µmol.g-1.min-1 respectively. In contrast, β-HAD activity was not different when 
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comparing TYPE 2 with CON averaging 5.0 ± 0.7 and 6.0 ± 0.7 µmol.g-1.min-1 respectively (see 
Figure 1 of Appendix 1). 
 
To determine if insulin resistance was associated with an index of mitochondrial capacity, we 
performed correlations between GIR and maximal activity of CS (see Figure 2 of Appendix 1). 
This revealed a significant correlation (r=0.62, P=0.01) (data not shown). To assess whether basal 
mitochondrial mRNA expression was related to mitochondrial capacity, we also performed 
correlations between mRNA expression and maximal activity of CS. Taking note that a higher 
delta CT is indicative of lower mRNA expression, tFAM mRNA was inversely correlated with 
CS (r=-0.52; P=0.04). Although not statistically significant, there was a tendency for NRF-1 to be 
correlated with CS (r=0.44; P=0.09) (see Appendix 1 for data). 
 
Basal & insulin stimulated intracellular signaling 
There was no difference in basal phosphorylated Akt when comparing CON with TYPE 2 
(Figure 2.4). However, whilst insulin increased (P<0.05) Akt phosphorylation in CON, this was 
not the case in TYPE 2 (Figure 4). Basal phosphorylation of FoxO1 on serine residue 256 (Ser256) 
was higher (P<0.05) in CON compared with TYPE 2 (Figure 2.5). Insulin did not increase 
phosphorylation at this residue in either group in-vivo (Figure 2.5).  Basal phosphorylation of 
FoxO1 on Threonine residue 24 (Thr24) was not different when comparing groups in the basal 
state in-vivo (Figure 2.6). However, whilst insulin stimulation increased (P<0.05) FoxO1 (Thr24) 
phosphorylation in CON, it did not do so in TYPE 2 (Figure 2.6).  
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Insulin stimulated mRNA Expression 
The insulin stimulated mRNA expression of PGC-1α and downstream metabolic and 
mitochondrial genes in-vivo are presented in Figure 2.7. The in-vivo mRNA abundance of the 
insulin stimulated expression (post-clamp) was expressed relative to basal (pre-clamp) for both 
CON and TYPE 2. We observed, in-vivo, that insulin decreased (P<0.05) the mRNA expression 
of PGC1-α, COX4, and NRF-1 in CON.  In contrast, insulin did not repress the expression of 
PGC1-α, COX4, and NRF-1 in TYPE 2. 
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Figure 2.2. Glucose Infusion Rate- human hyperinsulinaemic- 
euglycaemic clamp experiments. Mean glucose infusion rate during a 120 
min euglycemic, hyperinsulinemic clamp in patients with type 2 diabetes 
(TYPE 2) and healthy control subjects. *Difference (P<0.05) compared with 
CONTROL. Data are mean ± SE. 
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Figure 2.3. Basal gene (mRNA) expression prior to hyperinsulinaemic-euglycaemic 
clamp procedure. 
Basal mRNA expression of protein peroxisome proliferator-activated receptor γ 
coactivator-1α (PGC-1α), nuclear encoded cytochrome oxidase (COX4), forkhead box 
class-O (FoxO1), mitochondrial transcription factor A (tFAM), presenilins-associated 
rhomboid-like protein (PSARL), and nuclear respiratory factor-1 (NRF-1) in patients 
with type 2 Diabetes expressed relative to Control subjects. *Difference (P<0.05) 
compared with CONTROL. Data are mean ± SE. 
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Figure 2.4. Western blot analysis of Akt phosphorylation pre & post  
hyperinsulinaemic-euglycaemic clamp procedure. 
Pre (BASAL)- and post (INSULIN)-clamp, expression of phosphorylated Akt (Ser473) in 
patients with type 2 diabetes (TYPE 2) and healthy control subjects. *Difference 
(P<0.05) compared with CON (insulin). †Difference (P<0.05) compared with basal. 
Data are mean ± SE. Phospho-Akt. (Ser473) expressed as a ratio of total Akt. 
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Figure 2.5. Western blot analysis of FoxO1 (Ser 
256
) phosphorylation pre & 
post hyperinsulinaemic-euglycaemic clamp procedure. 
Pre (BASAL)- and post (INSULIN)-clamp, expression of phosphorylated FoxO1 
(Ser256) in patients with type 2 diabetes (TYPE 2) and healthy control subjects. 
*Difference (P<0.05) compared with CON . Data are mean ± SE. Phospho-FoxO1 
(Ser256) expressed as a ratio of total FoxO1. 
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Figure 2.6. Western blot analysis of FoxO1 (Thr 
24
) phosphorylation pre & post 
hyperinsulinaemic-euglycaemic clamp procedure. Pre (BASAL)- and post 
(INSULIN)-clamp, expression of phosphorylated FoxO1 (Thr24) in patients with type 2 
diabetes (TYPE 2) and healthy control subjects. *Difference (P<0.05) compared with 
CON. †Difference (P<0.05) compared with basal. Data are mean ± SE. Phospho-FoxO1 
(Thr24) expressed as a ratio of total FoxO1. 
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Figure 2.7. Insulin gene (mRNA) expression post clamp- insulin stimulated. Insulin 
stimulated (post-clamp relative to pre-clamp, preclamp = 1) mRNA expression of protein 
peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear encoded 
cytochrome oxidase (COX4), forkhead box class-O (FoxO1), mitochondrial transcription 
factor A (tFAM), presenilins-associated rhomboid-like protein (PSARL), and nuclear 
respiratory factor-1 (NRF-1) in patients with type 2 diabetes (TYPE 2) and healthy control 
subjects *Difference (P<0.05) compared with all other conditions. Data are mean ± SE. 
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DISCUSSION 
 
The aim of this chapter was to determine if the regulation of PGC-1α and associated OxPhos 
gene (genes hypothesized to be essential for mitochondrial biogenesis) expression, by insulin, is 
similar in skeletal muscle to those data reported in the literature, in the liver, i.e. the objective was 
to investigate if insulin’s regulation of PGC-1α mRNA in a FoxO1 dependant manner is 
conserved in skeletal muscle.  
 
The data obtained suggests that there is conservation between these two tissue types and indicates 
that the same signaling intermediates Akt, and FoxO1 have role in these processes. A 
confirmatory aspect of these initial data (the data that constitutes chapter 2) is realised via the 
observation that even in the small cohort studied, PGC-1α mRNA was reduced in the basal state 
in the context of type 2 diabetes (i.e. when comparing healthy non-diabetic individuals to diabetic 
individuals). This is in agreement with the data of Patti et al. (2003), and Mootha et al. (2003). 
Interestingly, the data of Patti et al., (2003), and Mootha et al. (2003) utilised gene set 
enrichment techniques a costly and time consuming means of identifying potential gene targets 
associated with the diabetic phenotype. Here, the data were obtained via standard RT-PCR 
techniques and as such adds support to the notion that PGC-1α mRNA quantification could in the 
future, be used as means of assessing an individuals diabetic status. Clearly, more experimental 
research in diabetic individuals needs to be undertaken before PGC-1α can be deemed a bone fide 
marker for Type 2 diabetes and insulin resistance, but it appears that PGC-1α has the potential to 
be used as marker of the diabetic phenotype in muscle tissue. 
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The data reported by Patti et al. (2003) also indicated that NRF-1 (a downstream gene target of 
PGC-1α) was also reduced basally in Type 2 diabetic muscle and first-degree relative of type 2 
diabetic patients. Again, the data presented in chapter 2 confirm the findings of Patti et al. (2003), 
and support the hypothesis that a repertoire of mitochondrial biogenesis related genes are 
dysregulated in Type 2 diabetes and that PGC-1α acts as a hierarchical regulator of OxPhos gene 
expression.  
 
The novel data presented here indicate that PGC-1α mRNA levels were not repressed post insulin 
stimulation in the patients with type 2 diabetes in contrast with the healthy individuals. The exact 
physiological consequence or role for this relative non-repression in the diabetic group remains to 
be elucidated.  
 
The aim of the experiments described in this Chapter was not to assess if PGC-1 α has a role in 
protection from oxidative stress. However, in an attempt to explain the physiological context of 
my findings, it is interesting to note that experiments recently conducted in endothelial cells 
suggest that PGC-1α over expression may serve to play a critical, protective role in vascular 
complications via its involvement in the transcriptional regulation of the mitochondrial 
antioxidant defense system (Valle et al., 2005). Also of interest, Manganese Superoxide 
Dismutase (MnSOD) an anti-oxidant defense gene has been proposed to be a transcriptional 
targeted of FoxO1 (Kops et al., 2002a). Although MnSOD was not measured in this study, the 
fact that it is a transcriptional target of FoxO1 adds support to the notion that FoxO1 and PGC-1α 
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may both function to afford some protection during times of increased oxidative stress and 
therefore their loss of sensitivity to insulin may serve a functional purpose in diabetes. 
 
In this regard, Valle et al. (2005) propose that high levels of PGC-1α may protect against the 
accumulation of reactive oxygen species (ROS) formation, and by virtue, reduce the likelihood of 
inducing apoptotic cell death pathways. The authors support this claim via the observation that 
the PGC-1α mRNA levels were reduced with small interfering RNA (siRNA). In cells where 
PGC-1α was knocked-down, the cells exhibited reduced expression of mitochondrial 
detoxification proteins.  
 
Whilst data from the literature suggests that FoxO1 promotes oxidative stress protection, and 
with consideration that the data described in this Chapter indicates that FoxO1 maintains a 
nucleic localisation via a reduced phosphorylation and thus maintains its transcriptional activity, 
it is clear that the suggested role that FoxO1 might have in protection from oxidative stress 
induction is insufficient to ameliorate the negative effects of oxidative stress on insulin 
sensitivity, if oxidative stress is the main antagonist in insulin resistance.  
 
In conclusion, the data presented suggest that unlike healthy, insulin sensitive humans, patients 
with type 2 diabetes are unable to down regulate PGC-1α mRNA and downstream OxPhos genes 
in their skeletal muscles in response to insulin. This appears due to the inability for insulin 
signaling to phosphorylate FoxO1 and shuttle it from the nucleus to the cytosol.  The exact 
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physiological consequence of this lack of responsiveness of OxPhos genes to insulin remains 
unclear, but could be related to cellular responses that are induced in an attempt to ameliorate the 
damaging effects of oxidative stress. 
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CHAPTER 3 
INTRODUCTION 
 
In the previous chapter, the role of FoxO1 on insulin mediated suppression of PGC-1α mRNA 
was examined in human biopsy specimens. In the present chapter, cell culture experiments were 
designed in order to determine if the actions of insulin on FoxO1 mediated PGC-1α mRNA 
expression were conserved in a better controlled cell culture skeletal muscle model. A cell culture 
approach was deemed appropriate as it was felt that this model would allow for the amelioration 
of the confounding variables involved in in-vivo experimentation, those being circadian 
oscillatory variation and the hormonal and metabolic changes in the environmental milieu that is 
associated with in-vivo physiology. Furthermore, I was unable to examine the nuclear abundance 
of total FoxO1 protein in human muscle (Chapter 2) due to insufficient tissue sample size, 
however, the use of the cell culture model described in this chapter would allow for assessment of 
nucleic FoxO1 abundance in-vitro.  
 
The literature suggested that endogenous PGC-1α mRNA expression is low in commonly 
utilized, commercially available animal derived muscle culture systems (Handschin et al., 2003; 
St-Pierre et al., 2003). To address this issue without resorting to transfection studies utilising 
exogenous PGC-1α plasmid DNA, which it was felt, would not provide a true analysis of 
FoxO1’s role in insulin mediated suppression of PGC-1α mRNA expression, human primary 
skeletal muscle myotube cultures were propagated from biopsy samples. 
 
Increased lipid storage within insulin sensitive tissues appears to be a central observation in the 
literature investigating the induction of insulin resistance in skeletal muscle in-vivo (Shulman 
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2000; Reynoso et al., 2003). Fatty acids have been shown to induce insulin resistant 
characteristics in in-vitro cell culture conditions (Schmitz-Peiffer et al., 1999; Storz et al., 1999), 
however this isn’t observed in all cell types (Lundgren  & Eriksson 2004; Kausch et al., 2003). 
Given that there is a strong association between lipid accretion in muscle and insulin resistance 
(Shulman 2000; Reynoso et al., 2003; Schmitz-Peiffer et al., 1999; Storz et al., 1999) both in-
vivo and in-vitro and the work of Patti et al. (2003) and Mootha et al. (2003) suggests that in-vivo 
PGC-1α expression is reduced in type 2 diabetics (Patti et al., 2003;Mootha et al., 2003) and first 
degree relatives of type 2 diabetics patients (Patti et al., 2003), it seemed reasonable to 
investigate if the saturated fatty acid palmitate could induce repression in PGC-1α in-vitro.  
 
Thus, the rationale for the experiments described in this chapter were: 1) to investigate if the 
saturated fatty acid palmitate could repress PGC-1α mRNA levels basally; and 2) investigate if 
palmitate treatment mirrors the perturbations imposed on the insulin signaling cascade observed 
in the previous chapter (Chapter 2) of this thesis with regard to reduced insulin stimulated FoxO1 
phosphorylation and non-repression of PGC-1α mRNA. 
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METHODS 
 
Primary human skeletal muscle cell culture 
Muscle tissue from the vastus lateralis was obtained from young, healthy, insulin sensitive 
subjects via percutaneous needle biopsy and immediately transferred to ice-cold Ham F-10 media 
(Gibco, Brooklyn, NY, USA). The tissue was washed three times in ice-cold Ham-F10 media to 
remove any traces of blood, and placed over ice in a sterile Petri dish. The tissue was covered 
with ~ 3 ml of 0.05% Trypsin/EDTA and minced. The homogenate was collected, diluted in 15 
ml of 0.05 % Trypsin/EDTA, agitated for 20 min and the supernatant collected and stored on ice. 
This procedure was repeated three times, the supernatants were pooled, filtered and then spun for 
7 min at 1600 g at room temperature. The cell pellet was re-suspended in growth media (Alpha 
MEM with 10% FCS, 0.5% penicillin-streptomycin, 0.5% Amphotericin B) and placed in an 
uncoated 75 cm2 cell culture flask and incubated for 30 min at 37oC (95% O2/5% CO2) to allow 
attachment of fibroblasts. The supernatant was collected and placed in another flask pre-coated 
with ECM and incubated as above for 24 h. Growth media was replenished every 48 hrs 
thereafter. Satellite cells appeared after ~ 7 days and were allowed to reach 60-70% confluence, 
at which point they were sub-cultured into separate dishes. When the myoblasts reached 70% 
confluence (approx 4-6 days), the growth media was replaced with differentiation media (2% HS, 
0.5% penicillin-streptomycin, 0.5% Amphotericin B). Myoblasts were maintained in 
differentiation media until fully fused myotube cultures were obtained. 
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Cell treatments and analytical measures. 
Myotube cultures were incubated in either vehicle ([VEH], 4% BSA [Sigma], 2% horse serum, 
0.5% penicillin-streptomycin, 0.5% Amphotericin B cocktail) or palmitate ([PALM], 4% BSA 
[Sigma], 0.75 mM palmitic acid [Sigma], 2% horse serum, 0.5% penicillin-streptomycin, 0.5% 
Amphotericin B cocktail) media for 8 h. After this time, cells were serum starved for 4 h and 
experiments performed. For insulin treatment, the appropriate cultures were stimulated with 50 
nM insulin for a period of 30 min for phospho-protein analysis or 8 h for mRNA analysis. For 
western blot analyses of total cell lysates, cells were lysed with ice-cold lysis buffer consisting of 
50 mM HEPES, 150 mM NaCl, 10 mM NaF, 1 mM Na3VO4, 5 mM EDTA, 0.5% Triton X-100, 
10% glycerol (v: v), 2 µg.ml-1 leupeptin, 100 µg.ml-1 phenylmethylsulfonyl fluoride (PMSF), and 
2 µg.ml-1 aprotinin and snap frozen in liquid nitrogen. For mRNA analyses, myotube cultures 
were lysed with 400ul RNAbee (Tel-Test, Friendswood, TX) and the lysate snap frozen in liquid 
nitrogen and stored at -80oC until subsequent extraction. 
RNA extraction and PCR analyses 
RNA Extraction and Real-Time-Polymerase-Chain-Reaction analysis were procedures were 
undertaken as detailed in the methods section of Chapter 2 (RNA Extraction and Real-Time-
Polymerase-Chain-Reaction analysis). 
Western blot analyses of whole cell lysate 
Preparation of whole cell lysate and Western blot analyses of whole cell lysate were undertaken 
as described in Chapter 2. 
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Nucleic protein isolation 
Nuclear proteins were extracted from myotubes using a technique described previously (Chan et 
al., 2004). Briefly, myotubes were homogenised in 500 µl of pre-chilled Buffer A (250 mM 
sucrose, 10mM Tris pH 7.5, 10 mM NaCl, 3 mM MgCl2, 1 mM dithiothreitol (DTT), 1 mM 
PMSF, and 2 ml/30 mg tissue protease inhibitor cocktail). The homogenate was spun at 500 g for 
5 min at 4°C. The supernatant containing cytosolic materials (crude fraction) was then removed 
and stored at -80°C until required. Then 500 µl of pre-chilled Buffer B (50 mM Tris pH 7.5, 1 
mM EDTA, 1 mM EGTA, 10% glycerol, 1% Triton X-100, 50mM MgCl2, 50 mM NaF, 5 mM 
Na pyrophosphate, 1 mM DTT, 1 mM PMSF, 2 ml/30 mg-1 tissue protease inhibitor cocktail) 
was added to re-suspend the remaining pellet. After 10 min incubation on ice with occasional 
mixing, the pellet mixture was then spun for 5 min at 3000 g at 4°C. The supernatant representing 
the nuclear fraction was extracted and stored at -80°C until required. Fraction purity was assessed 
by western blotting on Histone H1 as described previously (Chan et al., 2004). 
 
2-Deoxyglucose uptake 
Cells were serum starved overnight in α-MEM with 0.1% foetal bovine serum and treated with 
either vehicle or palmitic acid supplemented media. Following treatment, cells were equilibrated 
for 30 min in glucose free D-MEM and 0.1% BSA. Cells were then incubated in the presence or 
absence of insulin (50 nm) or 30 min after which the 3H-2-deoxyglucose solution was added for 
30 min. Cytochylastin B was added to a well from each plate to determine basal glucose uptake. 
The reaction was stopped by the addition of ice cold PBS and 0.1mM Phloretin. Cells were 
washed two times in ice cold 1 x PBS then lysed in 0.1% SDS. 400ul of lysate was added to 
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scintillation vials containing 4 ml of scintillation fluid, 3H concentration was then determined in a 
beta spectrometer. Ten µl of the remaining lysate was used to determine total protein 
concentration via Bradford method using Pierce reagents (A: B: C; 50: 49: 1. Perbio, Rockford, 
IL) and BSA for standard curve. 
 
Statistical Analysis 
Data are presented as mean ± Standard Error of Mean (SEM).  Statistical analysis consisted of a 
paired t-test for Figure 3.2 & 3.7, and two-way ANOVA (condition x treatment) for all other 
figures. Significance was accepted if P ≤0.05. Where analyses revealed a significant interaction, a 
Newman Keuls post-doc test was used to locate specific differences. All statistical analyses were 
performed with the application of Statistica for Windows (Statsoft, StatisticaTulsa OK). 
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RESULTS 
 
2-Deoxyglucose uptake 
2-deoxyglucose uptake was lower in insulin stimulated palmitate pre-treated myotubes compared 
with vehicle treated myotubes (Figure 3.1) 
 
Basal mRNA expression 
Consistent with the data in humans (Chapter 2), insulin stimulated mRNA expression of PGC-1α 
was lower (P<0.01) in palmitic acid treated (PALM) compared with vehicle (VEH) treated cells 
(Figure 3.2). 
 
Basal and insulin stimulated intracellular protein phosphorylation 
Consistent with the data obtained from human skeletal muscle, there was no difference in basal 
phosphorylated Akt when comparing VEH with PALM treated myotubes (Figure 3.3), insulin 
increased (P<0.05) Akt phosphorylation in VEH but not PALM treated myotubes (Figure 3.3). 
Basal phosphorylation of FoxO1 on (Ser256) was higher in VEH compared with PALM myotubes 
(Figure 3.4). In-vitro, insulin increased (P<0.05) FoxO1 (Ser256) phosphorylation in VEH but not 
PALM treated cells (Figure 3.4). Basal phosphorylation of FoxO1 (Thr24) residue was not 
different when comparing groups in the basal state (Fig. 3.5) in-vitro. However, whilst insulin 
stimulation increased (P<0.05) FoxO1 (Thr24) phosphorylation in VEH, it did not do so in PALM 
treated myotubes in-vitro (Figure 3.5). Insulin treatment decreased (P <0.05) the nuclear 
abundance (insulin induced cytosolic sequestration) of FoxO1 total protein in VEH, but not in 
PALM treated cells (Figure 3.6). 
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Insulin stimulated mRNA expression 
The insulin stimulated mRNA expression of PGC-1α in-vitro is presented in Figure 3.7.  The in-
vitro mRNA abundance of the insulin stimulated expression (post stimulation) was expressed 
relative to basal (pre-stimulation) for both VEH and PALM, respectively. It was observed in-
vitro that insulin decreased (P<0.05) the mRNA abundance of PGC-1α in VEH treated myotubes, 
but this was not the case in PALM treated cells. 
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Figure 3.1. In-vitro 3H-2-Deoxyglucose uptake in human primary 
skeletal muscle myotubes treated without and with palmitic acid 
Basal and insulin stimulated 2-deoxy-[U-3H]glucose uptake in human 
primary skeletal muscle myotubes treated with vehicle (VEH) or 
palmitate (PALM;). *Difference (P<0.05) compared with VEH. Data are 
mean ± SE. 
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Figure 3.2.  Basal PGC-1α mRNA expression in human primary 
skeletal muscle myotubes treated with and without palmitic acid. 
Basal mRNA expression of PGC-1α in vehicle (VEH) or palmitate 
(PALM) treated human primary skeletal muscle myotubes. PALM 
expressed relative to VEH (VEH=1). *Difference (P<0.05) compared 
with VEH. Data are mean ± SE. 
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Figure 3.3. Western blot analysis of Akt (Ser473) phosphorylation pre and post 
insulin, with and without palmatic acid treatment of human primary skeletal 
muscle myotubes BASAL and INSULIN stimulated expression of phosphorylated Akt 
(Ser473) in vehicle (VEH) and palmitate (PALM) treated human primary skeletal muscle 
myotubes). *Difference (P<0.05) compared with VEH . †Difference (P<0.05) compared 
with basal. Data are mean ± SE. Phospho-Akt (Ser473) expressed as a ratio of total Akt. 
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Figure 3.4. Western blot analysis of FoxO1 (Ser 256)  phosphorylation pre and 
post insulin, with and without palmitic acid treatment of  human primary 
skeletal muscle myotubes BASAL and INSULIN stimulated expression of 
phosphorylated FoxO1 (Ser256) in vehicle (VEH) and palmitate (PALM) treated 
human primary skeletal muscle myotubes. *Difference (P<0.05) compared with VEH 
. †Difference (P<0.05) compared with basal. Data are mean ± SE. Phospho-FoxO1 
(Ser256) expressed as a ratio of total FoxO1. 
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Figure 3.5. Western blot analysis of FoxO1 (Thr 
24
) phosphorylation pre and post 
insulin, with and without palmitic acid treatment  of human primary skeletal 
muscle myotubes. BASAL and INSULIN stimulated expression of phosphorylated 
FoxO1 (Thr24) in vehicle (VEH) or palmitate (PALM) treated human primary skeletal 
muscle myotubes. *Difference (P<0.05) compared with VEH . †Difference (P<0.05) 
compared with basal. Data are mean ± SE. Phospho-FoxO1 (Thr24) expressed as a ratio 
of total FoxO1. 
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Figure 3.6. Nucleic abundance of FoxO1 protein pre a post insulin, with and without 
palmitic acid treatment of  human primary skeletal muscle myotubes. BASAL and 
INSULIN stimulated nuclear abundance of total FoxO1 protein in human primary skeletal 
muscle myotubes treated with vehicle (VEH) or palmitate (PALM). *Difference (P<0.05) 
compared with VEH. †Difference (P<0.05) compared with basal. Data are mean ± SE. 
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Figure 3.7. PGC-1α gene expression in human primary skeletal muscle myotubes post 
insulin stimulation in presence of palmitic acid. Insulin stimulated (post insulin relative to 
pre-insulin, pre-insulin=1) mRNA expression of PGC-1α in primary human skeletal muscle 
myotubes treated with vehicle (VEH INSULIN) or palmitate (PALM INSULIN). 
*Difference (P<0.05) compared with preclamp or pre-insulin. Data are mean ± SE. 
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DISCUSSION 
  
The objective of this chapter was to investigate if the effects of insulin stimulation on PGC-1α 
gene expression were regulated in a similar way to those observed in-vivo, with the application of 
an in-vitro human primary skeletal muscle reductionism model of insulin resistance. 
 
In order to try and ameliorate the confounding effects of species’ differences, human primary 
myoblast cultures were propagated from muscle biopsy specimens obtained from healthy non-
insulin resistant subjects.  Part of the rationale for using healthy subjects to obtain the muscle 
cultures, as opposed to insulin resistant subjects was that it was deemed appropriate to induce the 
insulin resistant state, in culture, with an endogenous compound. This approach was employed as 
it better compares with the in-vivo situation with regard to the onset of insulin resistance i.e. 
healthy cultures, in which the insulin signaling cascade was patent, were induced towards an 
insulin resistant state with the saturated fatty acid; palmitate. These considerations were 
particularly pertinent given the findings of Krutzfeldt et al., (2000), who reported that that insulin 
action and signaling in cultured skeletal muscle cells from normoglycaemic lean insulin-resistant 
subjects was not different from that in cells from insulin-sensitive subjects. This suggests an 
important role of environmental factors in the development of insulin resistance in skeletal 
muscle.  
 
A lipocentric (lipid induced) paradigm with regard to the aetiology of insulin resistance has 
emerged in the literature over the past few years. Moreover, this paradigm has become a 
predominant hypothesis to explain the onset of insulin resistance in skeletal muscle. In this 
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regard, an early study conducted in C2C12 myotubes (Schmitz-Peiffer et al., 1999) reported lipid 
induced inhibition of insulin-stimulated signal transduction and glucose metabolism. This study 
reported a reduction in the activation of the insulin stimulated signaling intermediate Akt 
following 18 h of palmitate pre-incubation. Interestingly, these authors concluded that palmitate 
treatment induced a down-regulation of insulin stimulated Akt activation independently of any 
changes in upstream signaling, namely IRS-1. Storz et al. (1999) reported a down-regulation of 
insulin stimulated Akt activation (phosphorylation), GLUT4 translocation and glucose uptake in 
muscle cells pre-incubated with palmitic acid. Interestingly these observations (in contrast to 
those of Schmitz-Peiffer et al. 1999), also reported perturbations in insulin signaling at the level 
of IRS-1 activation (phosphorylation). The data related to IRS-1 activation and palmitate 
treatment by Storz et al. (1999), were subsequently confirmed by Reynoso et al. (2003) in a 
murine model of lipid induced insulin resistance. 
 
It is noteworthy that palmitate treatment does not always result in perturbation in insulin 
signaling and/or glucose uptake in-vitro (Kausch et al. 2003) and in-vivo (Lovejoy et al. 2002). 
Of note, this latter study (Lovejoy et al., 2002) investigated palmitate induced insulin resistance 
in-vivo and found that the treatments did not influence insulin sensitivity in lean individuals, but 
did have a negative impact on insulin sensitivity in overweight individuals. This again suggests 
that environmental factors play a significant role in the development of insulin resistance 
especially in the context of an already predisposing phenotype (i.e. overweight).  
 
The finding detailed in Chapter 3, support and confirm those data reported in the literature that 
suggest a role for saturated fatty acid induction of insulin resistance. In terms of metabolic 
parameters, the data presented here clearly show that palmitate pre-treatment reduces insulin 
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stimulated glucose uptake, following a relatively acute pre-incubation. The data presented here 
consolidate and expand on the literature as the data clearly shows an effect of palmitate that result 
in changes in transcriptional regulation of the PGC-1α, the hierarchical gene responsible for 
mitochondrial biogenesis.  
 
The observations that expand upon previous knowledge are those data that provide evidence of 
palmitate’s propensity to reduce PGC-1α gene expression basally (i.e. in the fed, non-insulin 
stimulated, state) in-vitro. This suggests that palmitate treatment is indeed a good means of 
experimentally inducing the insulin-resistant state, as the repression in-vitro compares well with 
the basal PGC-1α expression observed in type 2 diabetic subjects (Chapter 2), and those data 
reported in the literature (Mootha et al., 2004, Patti et al., 2003). As was the case in the healthy 
non-diabetic subjects, insulin repressed PGC-1α mRNA in control cultures, but failed to do so in 
palmitate treated myotubes. The reason for this non-repression of PGC-1α appeared to be related 
to an increased nucleic abundance of the Akt substrate FoxO1.  A discussion of the physiological 
relevance of this observation constitutes a significant part of Chapter 7. 
 
Of note, a recent publication provides evidence that the over-expression of PGC-1α  (Muira et 
al., 2006) results in degradation of muscle tissue and, moreover, this degradation is the result of 
adipocyte infiltration within muscle bed of the transgenic mice. It would appear that it is the 
regulation of PGC-1α at ‘normal’ levels is of key importance if normal muscle physiology is to 
be maintained since repression of PGC-1α is associated with diabetes and insulin resistance, 
whereas over-expression of PGC-1α mimics Luft’s disease, a disease associated with uncoupling 
of oxidative phosphorylation. In summary, the results from this chapter confirm the observations 
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presented in humans that show that insulin resistance is associated with a failure of insulin to 
suppress PGC-1α mRNA expression, likely due to an inability for FoxO1 to be phosphorylated 
and sequestered from the nucleus to the cytosol.  
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CHAPTER 4 
INTRODUCTION 
 
The activity of the signaling intermediate Akt is essential for the insulin stimulated negative 
regulation of FoxO1 induced gene expression. Akt 1 isoform and Akt 2 isoform knockout mice 
have been generated and described in the literature (Cho et al., 2001a; Cho et al.,2001b; Chen et 
al., 2001). The original report by Cho et al., (2001a) suggested that Akt 2 knockout mice are 
insulin resistant and exhibit a diabetes mellitus like syndrome. In contrast, whilst ablation of Akt1 
resulted in similar growth retardation (Cho et al., 2001b, Chen et al., 2001) to that reported in 
Akt 2 null mice (Cho et al., 2001a), Akt 1 ablation did not result in a perturbation of insulin 
sensitivity or regulation of glucose homeostasis.  
 
Given that the data described in Chapters 2 & 3 suggested that insulin stimulated Akt 
phosphorylation was reduced in: 1) the diabetic subjects from the in-vivo human clamp 
experiments (Chapter 2); and 2) in the palmitate treated in-vitro human primary skeletal muscle 
culture experiments (Chapter 3) it seemed reasonable to utilize the Akt 2 transgenic model 
described by Cho et al., (2001a) to further support the main findings described in Chapters 2 and 
3. In this regard, it was hypothesized that Akt 2 transgenic mice may display similar attributes to 
both the diabetic subjects (from Chapter 2) and the palmitate treated human skeletal muscle 
myotubes with regard to the FoxO1 mediated regulation of PGC-1 alpha mRNA in response to 
insulin stimulation (Chapter 3). 
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Additionally, reports in the literature (Kamei et al., 2004) at the time of conducting initial 
experiments in the Akt 2 knockout experiments suggested that transgenic FoxO mice (FoxO 
over-expressed in muscle) shared similar phenotypic features with the Akt animals. In this regard, 
these lines of transgenic mice are both smaller in size and they both exhibit a certain degree of 
insulin resistance compared with their littermate controls (Cho et al., 2001a; Kamei et al 2004). It 
was deemed appropriate to examine the expression of genes associated with muscle atrophy 
(MAFbx and Murf1) in order to determine whether there were common effectors of this response. 
The rationale for this approach was one of wanting to set the stage for the work detailed in 
Chapter 5. It was also deemed appropriate to analyze a gene (Raptor) that is potentially repressed 
by FoxO (Jia et al., 2004). DAF 15 is repressed by DAF 16, the C.elegans orthologs of Raptor 
and FoxO1 respectively  (Jia et al., 2004). Evidence to date suggests that Raptor is required for 
propagation of the translation/initiation pathway and as such its expression may correlate with 
tissue mass (Hara et al., 2002; Sarbassov et al., 2002).  
 
Since the general consensus in the literature suggests that phosphorylation of FoxO1, and thus, 
repression of its transcriptional activity is Akt dependant we hypothesized that Akt 2 knockout 
animals would exhibit a reduced ability to suppress PGC-1α mRNA expression levels in the 
insulin stimulated state. 
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METHODS 
 
Generation and experimental treatment of transgenic mice  
Akt2 knockout mice were developed as previously described (Cho et al., 2001a).  Akt2 -/- and 
wild type littermate control mice were fasted overnight and the following morning injected with 1 
mU/g-1 body mass insulin into the intraperitoneal space. Mice were then anesthetized (50 mg.kg-1 
pentobarbital) and gastrocnemius muscle was harvested and snap frozen in liquid nitrogen, 20 
min post insulin injection. 
 
Protein extraction and western blot analyses  
Muscle homogenate preparation and western blot analyses were undertaken as described in 
Chapter 2.  
 
Nucleic protein isolation 
Nucleic protein isolation was undertaken as described in Chapter 3.  
 
mRNA extraction and RT-PCR analyses  
RNA extraction and real-time polymerase chain reaction analysis for mRNA abundance were 
undertaken as described in Chapter 2. 
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Statistical Analysis 
Data are presented as mean ± Standard Error of Mean (SEM).  Statistical analysis consisted of a 
paired t-test for figures 4.1, 4.2, 4.5, 4.6 & 4.7, and two-way ANOVA (condition x treatment) for 
all other figures. Significance was accepted if P ≤0.05. Where analyses revealed a significant 
interaction, a Newman Keuls post-hoc test was used to locate specific differences. All statistical 
analyses were performed with the application of Statistica for Windows (Statsoft, 
StatisticaTulsa OK). 
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RESULTS 
 
Basal and insulin stimulated mRNA expression 
In agreement with the in-vivo and in-vitro data, the basal mRNA expression of PGC-1α was 
lower (P<0.01) in Akt 2 -/- compared with WT mice (Figure 4.1). Moreover, insulin stimulation 
decreased (P<0.05) the mRNA expression of PGC-1α in WT, but failed to do so in Akt 2 -/- mice 
(Figure 4.2). The basal expression of these genes associated with atrophy (MAFbx and Murf-1) 
was determined in order to assess the basal effect of knocking out Akt on these parameters. The 
effect of insulin on expression of the atrogenes; MAFbx and Murf 1, and one of the upstream 
regulators of translation/initiation; Raptor, were also assessed at the mRNA level. As can be seen 
in Figure 4.5, basal expression of Murf-1 and MAFbx were significantly higher (p<0.05) in the 
Akt2 -/- mouse muscle. Concomitantly, basal Raptor mRNA expression was significantly lower 
in Akt2 -/- mouse muscle (Figure 4.7A). The insulin stimulated MAFbx mRNA expression was 
not different between WT and Akt2 -/- animals, however, Murf-1 mRNA was significantly 
reduced (P <0.05) in WT but not Akt2 -/- mice post insulin stimulation. Insulin stimulation 
induced a significant increase (P<0.05) in Raptor mRNA (figure 4.7B) in WT but failed to elicit 
increases in Raptor mRNA in muscles from Akt2 -/- mice. 
 
 
Basal and insulin stimulated intracellular protein phosphorylation 
As expected, insulin phosphorylated (P<0.05) Akt in wild type but not Akt2 -/- mice (Figure 
4.2A). Likewise, insulin phosphorylated (P<0.05) FoxO1 (Ser256) (Figure 4.2B) and FoxO1 
(Thr24) (Figure 4.3A) in wild type but not Akt2 -/- mice. Accordingly, insulin reduced (P<0.05) 
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the nucleic abundance of FoxO1 in wild type, but not Akt2 -/-, mice (Figure 4.3B). The protein 
abundance of Raptor was significantly lower (P<0.05) in Akt 2 -/- muscle upon insulin 
stimulation (Figure 5.8) when compared to WT mouse muscle, and there was a tendency for a 
reduction in basal protein expression. In WT mouse muscle, insulin elucidated a three-fold 
increase in Raptor protein, whereas Raptor abundance in Akt -/- mice did not change. As a proxy 
measure of Raptor activity, we measured the downstream kinase p70S6K (Figure 5.9). There was 
no difference in total p70S6K abundance basally or upon insulin stimulation (Figure 5.9), 
however, phosphorylation of p70S6K (Thr389) was significantly increased in wild type muscle, 
but not Akt -/- muscle 
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Figure 4.1. Basal (prior to insulin stimulation) PGC-1α mRNA  
expression in muscle  of wildtype and Akt 2 muscle specific knockout 
mice. Basal PGC-1α mRNA expression in wild-type (WT BASAL) and 
Akt knockout (KO BASAL) muscle. *Difference (P<0.05) compared with 
WT. 
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Figure 4.2. PGC-1α mRNA expression in muscle post insulin treatment 
of  wildtype and Akt 2 muscle specific knockout  mice. Insulin stimulated 
PGC-1α mRNA expression in wildtype (WT INSULIN) and Akt knockout 
(KO INSULIN) skeletal muscle. *Difference (P<0.05) compared with WT. 
 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
WT INSULIN KO INSULIN
P
G
C
-1
a
lp
h
a
 m
R
N
A
 e
x
p
re
ss
io
n
 r
el
a
ti
v
e 
to
 W
T
 
B
A
S
A
L
 =
 1
*
P
G
C
-1
a
lp
h
a
 m
R
N
A
 e
x
p
re
ss
io
n
 r
el
a
ti
v
e 
to
 W
T
 
B
A
S
A
L
 =
 1
 
 73
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Akt (Ser473) [A] & FoxO1 (Ser 256)  [B] phosphorylation  
pre (basal) and post (insulin) insulin treatment of  wildtype and Akt 2  muscle 
specific knockout mice. Phosphorylation of Akt (Ser473), FoxO1 (Ser256) in basal 
(BASAL) and insulin stimulated (INSULIN) gastrocnemius skeletal muscle obtained from 
wild-type (WT) and Akt2 knockout (Akt2 −/−) mice. *Difference (P<0.05) compared 
with WT. †Difference (P<0.05) compared with basal. Data are mean ± SE. Phospho-
proteins (Phospho-Akt, FoxO1 Ser) expressed as a ratio of total-Akt and FoxO1 proteins 
respectively. 
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FIGURE 4.4. FoxO1 (Thr 
24
) phosphorylation [A], and total nucleic abundance of 
FoxO1 [B] pre (basal) and post (insulin) insulin treatment of wildtype and Akt 2 
muscle specific knockout mice. Phosphorylation of FoxO1 (Thr24) and FoxO1 nucleic 
abundance in basal (BASAL) and insulin stimulated (INSULIN) gastrocnemius skeletal 
muscle obtained from wild-type (WT) and Akt2 knockout (Akt2 −/−) mice. *Difference 
(P<0.05) compared with WT. †Difference (P<0.05) compared with basal. Data are mean 
± SE. Phospho-proteins (FoxO1 [Thr24]) expressed as a ratio of total-FoxO1 proteins. 
Nucleic FoxO1 expressed as a ratio of Histone 1. 
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Figure 4.5. Basal Murf1 and Mafbx (atrogenes) mRNA  expression in muscle 
of wildtype (WT) and Akt 2 muscle specific knockout mice (Akt2-/-). Murf-1 
and Mafbx mRNA expression in wild-type (WT) and Akt 2 knockout (KO) 
muscle. *Difference (P<0.05) compared with WT (wild type values expressed as 
1, and denoted by dotted line). 
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Figure 4.6. Insulin stimulated Murf1 and Mafbx (atrogenes) mRNA  
expression in muscles of wildtype (WT) & Akt 2 muscle specific knockout 
mice (KO). Murf-1 & Mafbx mRNA expression in wild-type (WT) and Akt 2 
knockout (KO) muscle. *Difference (P<0.05) compared with WT (wildtype 
vaules expressed as 1, and denoted by dotted line). 
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Figure 4.7. Basal and Insulin stimulated Raptor mRNA  expression in 
muscle of wildtype (WT) and Akt 2 muscle specific knockout mice (KO). 
Basal (A) & insulin stimulated (B) Raptor mRNA expression in wild-type (WT) 
and Akt 2 knockout (KO) muscle. *Difference (P<0.05) compared with WT. 
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Figure 4.8. Basal (BASAL) & insulin (INSULIN) stimulated Raptor 
protein expression in the skeletal muscle of WT and Akt 2 knockout (Akt 
-/-) mice. Total Raptor protein abundance in WT (black bars) and Akt -/- 
mice (white bars). There was a tendency for a reduced Raptor protein 
abundance in Akt -/- compared to wild-type mice. Insulin induced a 
significant (P<0.05) increase in Raptor protein abundance in WT but not Akt 
-/-.*Difference (P<0.05) compared with WT. †Difference (P<0.05) compared 
with basal. 
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Figure 4.9  p70 S6K (Thr389) phosphorylation  pre (BASAL) and post 
(INSULIN) insulin treatment of  wildtype & Akt 2  muscle specific 
knockout mice. Phosphorylation of p70S6K (Thr 389) in basal (BASAL) 
and insulin stimulated (INSULIN) gastrocnemius skeletal muscle 
obtained from wild-type (WT) and Akt 2 knockout (Akt2 −/−) mice. 
*Difference (P<0.05) compared with WT. †Difference (P<0.05) 
compared with basal. Data are mean ± SE. Phospho-protein expressed as 
a ratio of total-p70S6K protein. 
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DISCUSSION 
 
The objective of this chapter was to investigate if the effects of insulin stimulation on PGC-1α 
gene expression were directly regulated by FoxO1 in an Akt dependant manner. This was 
assessed using muscle specific, Akt 2 knockout (Akt 2-/-) mice.  
 
Briefly, it was hypothesised that Akt 2 -/- animals would exhibit levels of PGC-1α mRNA 
expression both basally and upon insulin stimulation consistent with both of the diabetic models 
described in Chapters 2 and 3.  It was further hypothesized that this non-repression of PGC-1α 
would be accompanied by a concomitant reduction in insulin stimulated FoxO1 phosphorylation. 
The data obtained mirrored very closely those observed in the type 2 diabetic muscles and the 
experimentally induced insulin resistant human, skeletal muscle myotubes. These data were 
somewhat expected, given the essential role that Akt has in propagating insulin signaling to its 
downstream effector FoxO1.  
 
It is interesting that Akt 2 -/- animals are smaller than their wild-type control animals. Recently, 
Kamei et al., (2004) produced muscle specific FoxO1 over-expression mice and these animals 
were small, and have greater FoxO1 transcriptional activity (as evidenced by an increase in PGC-
1α mRNA similar to the Akt 2-/- animals in this chapter. Given this similarity in the 
characteristics of these animals, the mRNA of the atrogenes Murf1 and MAFbx were measured in 
the basal and insulin stimulated state. Both Murf-1 and MAFbx have been reported to be 
associated with muscle atrophy and their expression is repressed in an insulin stimulated, FoxO 
dependant manner. Basally, both Murf-1 and MAFbx were significantly higher in Akt 2 -/- 
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animals, due to greater FoxO1 activity, as hypothesized. Murf 1 mRNA was repressed by insulin 
in wild type mice but not in the Akt 2 -/- animals. There was no reduction in MAFbx mRNA post 
insulin stimulation in wild type mice when compared with Akt 2-/- mice. Previous work has 
identified MAFbx as being a bone fide target of FoxO1 transactivation (and this will be 
confirmed in the next chapter of this thesis Chapter 5). The data presented in this chapter, it can 
indicate that acute insulin stimulation does not have an effect on MAFbx expression irrespective 
of patent Akt signaling. 
 
A report by Jia et al. (2004) suggested that the regulation of Raptor, a protein that complexes 
with mTOR to propagate signals downstream that allow translation/initiation to occur (Hara et al. 
2002; Sarbassov et al., 2002), is under the control of FoxO in C. elegans. In the present study, 
evidence for a conserved response was observed with regard to FoxO’s regulation of Raptor.  In 
the basal (non insulin stimulated) state, Raptor mRNA was reduced significantly within the 
context of increased FoxO activity (the Akt 2-/- animals), as Akt could no longer exert its 
inhibitory role on FoxO. It was of interest that, in the insulin stimulated state; Raptor mRNA and 
protein levels were increased significantly in WT, but not in the Akt 2-/-, animals. This suggests 
that insulin induced the rapid transduction of both Raptor mRNA and protein. Insulin has been 
reported to regulate aspects of the translation initiation pathway via its promotion of Raptors’ 
physical associated with mTOR. When insulin stimulated, the Raptor/mTOR complex propagates 
signals to downstream effectors of translation initiation. It would appear that insulin expedites 
this response to increase Raptor expression and Akt ablation impacts upon the ability of insulin to 
induce this response. Akt has been shown to regulate cell size via its hypertrophic properties, 
which, in the most part, are highlighted by its ability to increase translation/initiation pathways. It 
is also important to note that Akt negatively regulates FoxO1s transactivation of the atrophic 
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gene MAFbx. Thus, it could be suggested that Akt regulates cell size via its ability to: 1) suppress 
FoxO (ameliorating atrophic gene expression); and 2) by inducing translation/initiation that 
promotes growth.  
 
The finding described in this chapter are largely confirmatory, but nonetheless important, given 
the nature of the previous data obtained in muscle from type 2 diabetic patients and 
experimentally induced insulin resistance in culture. The combined data of Chapters 2, 3 and 4 
suggest that there is not only conservation across species regarding FoxO1’s role in the regulation 
of PGC-1 gene expression, but that the observations can be replicated both in-vivo and in-vitro. 
The work of this chapter also provided the impetus for direction for Chapter 5, as its appeared 
that there was a bone fide repression of Raptor mRNA in Akt 2-/- animals and therefore within 
the context of increased FoxO activity. 
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CHAPTER 5 
INTRODUCTION 
 
Loss of skeletal muscle tissue is a clinical manifestation of many conditions and diseases 
including aging, cancer, sepsis, HIV and diabetes (Price 2003), and important progress has been 
made in understanding the molecular regulation of both catabolism and anabolism within skeletal 
muscle (Hoffman & Nader 2004). The ubiquitin ligase MAFbx (atrogin-1) promotes skeletal 
muscle protein degradation in response to glucocorticoid (Stitt et al., 2004; Sandri et al., 2004), 
and contributes toward muscle atrophy via proteosomal degradation of MyoD (Tintignac et al 
2005). MAFbx is a target gene of FoxO transcription factors (Stitt et al., 2004; Skurk et al., 
2005).  As discussed previously, FoxO1 is expressed in insulin sensitive tissues such as skeletal 
muscle, liver, and adipose tissue (Imae et al., 2003) and is an important target of insulin signaling 
downstream of Akt (see Chapters 2-4). Previous chapters described in detail how insulin 
negatively regulates FoxO1 transactivation of target genes, in such a way that upon insulin 
stimulation, Akt phosphorylates FoxO1, resulting in its exclusion from the nucleus. These data 
(Chapters 2-4) were consistent with many previous observations (Rena et al., 2001; Biggs et al., 
1999; Takashi et al., 1999; Rena et al., 2001; Brunet et al., 1999).  Importantly when FoxO1 is 
extruded from the nucleus it undergoes subsequent proteosomal degradation (Matsuzaki et al., 
2003) following ubiquitination by Skp2 (Huang et al., 2005). 
 
The decreased protein synthesis observed in skeletal muscle in various catabolic conditions is 
associated with defects in mRNA translation initiation (Cooney et al., 1997; Shah et al., 2000). 
The translation of mRNA is divided into three steps: initiation, elongation, and termination (Lang 
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et al., 2005) and is facilitated and regulated by eukaryotic initiation factors (Lang & Frost 2005). 
The stable heterotrimeric complex consisting of eIF4E, eIF4G and eIF4A, which form the active 
eIF4F molecule, plays a critical role in peptide chain orientation by regulating recruitment of 
capped mRNAs to the 43S pre-initiation complex (Pain, 1986). The eukaryotic initiation factor-
4E (eIF4E) and its inhibitory protein, eukaryotic initiation factor-4E-binding protein-1 (eIF4E-
BP1) have been suggested to be critical for the regulation of translation initiation (Lawrence & 
Abraham 1997). eIF4E-BP1 is a phosphoprotein that, in its non-phosphorylated state, forms a 
tight association with eIF4E and prevents its interaction with eIF4G, and recruitment to the 43S 
pre-initiation complex. When hypo-phosphorylated, as would be the case in the absence of 
nutrients or growth factors, eIF4E-BP1 association with eIF4E serves to repress translation 
(Schalm et al., 2003). In contrast, when phosphorylated, eIF4E-BP1 dissociates from eIF4E and 
allows the recruitment of capped mRNA and translation initiation (Rhoads 1999). This complex 
interaction is thought to represent a rate-limiting step in protein synthesis which can, in part, be 
ascribed to the fact that eIF4E is the least abundantly expressed subunit (Duncan et al., 1987).  
eIF4E-BP1 contains at least six phosphorylation sites, including two threonines (Thr37/46) that are 
hierarchical regulatory sites activated by mammalian Target of Rapamycin (mTOR) signaling 
(Fadden et al., 1997; Heesom et al., 1998; Gingras et al., 2001; Martin & Blenis 2002).  In 
response to Akt activation, mTOR forms a complex with Raptor, a 150-kD polypeptide (Kim et 
al., 2002), and then phosphorylates eIF4E-BP1 (30). Raptor is critical for TOR signaling in-vivo 
(Kim et al., 2002) and is absolutely required for the mTOR-catalysed phosphorylation of eIF4E-
BP1 in-vitro (Hara et al., 2002; Nojima et al., 2003). 
 
Recent work in Drosophila (Hay & Sonnenberg 2004; Junger et al., 2003) and C. elegans 
(Teleman et al., 2005; Jia et al., 2004) suggests that orthologs of eIF4E-BP1 and Raptor are 
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targets of FoxO proteins. These observations raise the possibility that, in mammalian skeletal 
muscle, FoxO1 may not only contribute towards catabolic processes via activation of ubiquitin 
ligases, but also via repression of anabolic pathways. Using both C2C12 mouse myoblasts stably 
expressing FoxO1-ER fusion proteins that are rapidly activated by hydroxytamoxifen (4-OH 
TAM) treatment and transgenic mice that specifically over express constitutively active FoxO1 in 
skeletal muscle (FoxO1++/+ mice), I tested the hypothesis that FoxO1 inhibits mTOR signaling 
and protein synthesis. The data contained in this chapter show that FoxO1 increases total (but not 
phospho-) eIF4E-BP abundance, resulting in hypo-phosphorylation of eIF4E-BP. These 
observations occur in the face of a decreased abundance mTOR and Raptor, upstream regulators 
of eIF4E-BP phosphorylation, and concomitantly with reduced protein synthesis, as measured by 
[14 C] Phenylalanine incorporation. 
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METHODS 
 
C2C12 cells and cell culture 
C2C12 skeletal muscle myoblasts stably expressing FoxO-ER fusion proteins were described 
previously (Bastie et al., 2005). In brief, C2C12 were stably transfected with the empty pBABE 
retrovirus or pBABE vectors expressing fusion proteins containing either a constitutively active 
form (where three Akt phosphorylation sites [Thr 24, Ser 256 and Ser 319] are replaced by 
alanines) or a transcriptionally inactive form (where His215 is replaced with arginine and reduces 
DNA binding) of human FoxO1 in-frame with a modified (tamoxifen-specific) version of the 
murine estrogen receptor-α ligand binding domain.  Cells were selected with puromycin and 
colonies pooled for studies, as reported previously (Bastie et al., 2005).  Fusion proteins are 
restricted to the cytoplasmic space until activation by treatment with 4-OH tamoxifen. 
 
Cells were maintained in proliferation media consisting of Dulbecco’s modified Eagle’s Medium 
supplemented with 10% fetal calf serum and 1% penicillin/streptomycin cocktail at 370C and 5% 
CO2 until confluent. Confluent myoblast cultures were rinsed in 1X PBS, dissociated with 0.05% 
trypsin, pelleted (1600 rpm for 5 min), rinsed in warm 1X PBS and seeded into experimental 
plates pre-coated with 0.2% gelatin (100 mm plates for protein extraction and 
immunoprecipitation, 6-well plates for RNA extraction, and 12-well plates for protein synthesis 
experiments). When experimental cultures were 80% confluent, proliferation medium was 
changed to differentiation medium consisting of Dulbecco’s modified Eagle’s medium 
supplemented with 2% horse serum and 1% penicillin/streptomycin cocktail. On day 4, fully 
fused myotubes cultures were supplemented with 10% FBS for 24 h to induce the fed state, 
ameliorate effects of endogenous FOXO proteins and drive protein synthesis. Following 24 h of 
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FBS treatment, cells were treated with 1 µM 4-hydroxytamoxifen in order to activate FoxO1-ER 
fusion proteins and promote their translocation to the nucleus or with vehicle (DMSO) for 0, 8, 
12 and 24 h.   
 
Transgenic Animal Experiments 
The generation and phenotype of the FoxO1++/+ mice have been extensively reported previously 
(Kamei et al., 2004).  FoxO1+ and WT mice were anaesthetized via 2.5% Avertin (0.017 mL/g 
body weight, i.p.).  Gastrocnemius muscles were then excised bilaterally using aseptic technique, 
weighed and stored at -80º C until further processing.  All animals were housed in hepa-filtered 
cages, exposed to a 12:12 h light dark cycle (lights on at 0800 hours), and provided a standard 
rodent diet and water ad libitum.  All surgical procedures were performed between 0800 and 
0930 h.   
 
Western Blot analyses 
For Western blot analyses of total cell lysate from C2C12s, cells were lysed with ice-cold lysis 
buffer consisting of 50 mM HEPES, 150 mM NaCl, 10 mM NaF, 1 mM Na3VO4, 5 mM EDTA, 
0.5% Triton X-100, 10% glycerol (v: v), 2 µg.mL-1 leupeptin, 100 µg.mL-1 phenylmethylsulfonyl 
fluoride, and 2 µg.mL-1 aprotinin. Gastrocnemius muscle from the animals were homogenised in 
the same buffer as the C2C12 cultures with a Polytron homogenizer. Homogenates were spun at 
16,000 g for 60 min at 4oC and the supernatant was removed and rapidly frozen in liquid 
nitrogen. Protein concentration of the muscle lysates was subsequently determined (Pierce, 
Rockford, IL, USA). Lysates were solubilised in Laemmeli sample buffer and boiled for 5 min, 
resolved by SDS-PAGE on 6%, (mTOR, Raptor) 12% (p70S6K1) and 18% (eIF4E-BP1, eIF4E), 
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polyacrylamide gels, transferred to a nitrocellulose membrane, blocked with 5% milk and 
immunoblotted overnight with total-Raptor, total-eIF4E-BP1, phospho eIF4E-BP (Thr37/46), total-
mTOR, phospho-mTOR (Ser2448), total-p70S6K, phospho-S6K1 (Thr389) antibodies (1:1000; Cell 
Signaling, Beverley, MA) and total-eIF4E (BD Biosciences). After incubation with horseradish 
peroxidase-conjugated secondary antibody (1:2000; Amersham Biosciences, Castle Hill, NSW, 
Australia), the immunoreactive proteins were detected with enhanced chemiluminescence (Perkin 
Elmer, Rowville, Victoria, Australia) and quantified by densitometry.  
 
C2C12 immunoprecipitation analysis 
Given that the dominant negative C2C12 FoxO1 cells (FoxO1-215) appeared to act as good 
controls for comparison with the constitutively active FoxO1 cells (CA-FoxO1), I opted to only 
utilise these cell lines for immunoprecipitation studies. Cell cultures were treated in exactly the 
same way those for whole cell lysate analysis, but the experiments were only conducted over a 12 
h period alone. Following 24 h of 10% FBS supplementation, cultures were treated for 0 or 12 h 
with/without 4-OH TAM or DMSO (-); cells were lysed in buffer previously described (Hara et 
al., 2002). This buffer has NP40 substituted for Triton X-100, and allows for assessment of 
associated/bound Raptor/mTOR via immunoprecipitation. Briefly, buffer A constituents were as 
follows: buffer A (20 mM Tris, 20 mM NaCl, 1 mM EDTA, 20 mM β-glycerophosphate, 5 mM 
EGTA, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride [PMSF], 2 µg/ml aprotinin, 1 
µM leupeptin [pH 7.4]) and 1% NP40. The cell lysates were left on ice for 10 min then 
centrifuged at 10,000 g for 30 min at 4°C. 1000 µg/ml sample was incubated overnight at 4oC 
with anti mTOR antibody (Cell Signaling). Protein A sepharose beads were added to the sample 
and incubated for 4 hours at 4oC with gentle rocking. The protein A sepharose/sample complex 
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was spun in a centrifuge for 30 seconds and washed twice with buffer A and twice with buffer B 
(10 mM Hepes, 50 mM β-glycerophosphate, 50 mM NaCl [pH 7.4]) on ice. The pellet was re-
suspended in 2X SDS sample buffer, mixed with a vortex, centrifuged for 1 minute and heated to 
85oC for 5 minutes and placed on ice. Samples were resolved on 4% SDS-PAGE polyacrylamide 
gels, transferred to nitrocellulose membrane, blocked with 5% milk, washed 5 times with TBST 
and incubated overnight with anti-Raptor antibody (Cell Signalling). After overnight incubation 
in the primary antibody, membranes were incubated in horseradish peroxidase-conjugated 
secondary antibody (1:2000; Amersham Biosciences, Castle Hill, NSW, Australia), and the 
immunoreactive proteins were detected with enhanced chemiluminescence (Perkin Elmer, 
Rowville, Victoria, Australia) and quantified by densitometry. 
 
Gene expression studies 
Day 4 differentiated, myotube cell cultures were treated with 1 µM 4-OH TAM for 0, 8, 12, and 
24 h or vehicle (DMSO). Animal tissues were homogenised with a polytron homogeniser. 
Following treatments (cell culture) and homogenisation (animal tissue), RNA was extracted via 
an on-column RNA isolation kit (Absolutely RNA Miniprep Kit, Stratagene, La Jolla, CA, USA) 
according to manufacturers instructions.  RNA samples were reverse transcribed using a thermal 
cycler (Perkin Elmer GeneAmp PCR 2400 Thermal Cycler, Rowville, Victoria, Australia) with 
TaqMan Reverse Transcription Reagents (Applied Biosystems, Foster City CA, USA) in 40 µl 
reaction mixtures containing 1 x TaqMan RT Buffer, 5.5 mM MgCl2, 500 µM 2’-
deoxynucleoside 5’-triphosphate, 2.5 µM random hexamers, 0.4U/µl-1 RNase inhibitor, 1.25 U/ 
µl-1 multiscribe reverse transcriptase. Control (reverse transcriptase negative) samples were also 
made and included in all PCR analyses to check for genomic DNA contamination. 
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Protein synthesis studies 
Protein synthesis experiments were performed as described by Franch et al. (2003) with 
modifications. Briefly, day 4 myotube cultures were incubated in differentiation media 
supplemented with 0.6 mM phenylalanine (cold Phe) and 10% serum for 2 h prior to the addition 
of 0.5 µCi [14 C]-phenylalanine (hot Phe) per well for 2, 8, 12 & 24 h. The appropriate constructs 
(pBABE-empty vector, FoxO1-215 & CA-FoxO1) were activated (or not) with 1 µM 4-OH-
TAM upon addition of [14 C]-phenylalanine. Following the time course, cells were washed x 3 
with cold (1X) PBS and lysed in 600µl of 10% trichloracetic acid (TCA) and placed on ice for 60 
min. The plates were thoroughly scraped and the lysate spun in a centrifuge at 16000 rpm for 15 
min (4oC). Following centrifugation, the supernatant was discarded and the pellet washed x 3 
with ethanol: ether (1:1 ratio). The pellet was solubilised overnight in 0.6 ml of 0.3 M NaOH at 
4oC. Following overnight solubilisation, 0.5 mL of cell lysate was added to 4.0 ml scintillation 
solution (Starscint Perkin-Elmer, Boston, MA, USA), and the incorporated [14 C]-phenylalanine 
from the lysed pellet assessed via radioisotope scintillation. Counts were expressed against total 
protein.  
 
Statistical Analysis  
Data analyzed using a one way or two-way analysis of variance (ANOVA) with repeated 
measures (Statistica®, Tulsa, OK), with significance accepted with a P value of <0.05. If 
analyses revealed a significant interaction, a Newman Keuls post-hoc test was used to locate 
specific differences.  Data are presented as means ± SEM 
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RESULTS 
 
eIF4E-BP1 and Raptor are transcriptional targets of FoxO1 in skeletal 
myotubes 
To study the effects of FoxO1 on mTOR signaling in muscle cells, I employed C2C12 cells 
stably expressing either a constitutively active form of FoxO1 (CA-FoxO1), or a transcriptionally 
inactive form of FoxO1 (FoxO1-215) in-frame with a modified form of the estrogen receptor 
ligand binding domain that responds selectively to 4-OH TAM (Bastie et al., 2005). Previous 
studies with these cells have shown that fusion proteins are restricted to the cytoplasmic space in 
the absence of ligand and then rapidly translocate to the nucleus upon treatment with 4-OH TAM 
(Bastie et al., 2005). While FoxO proteins can prevent myocyte differentiation and fusion (Hribal 
et al., 2003), this model allowed us to maintain FoxO-ER fusion proteins in an inactive state 
during myoblast proliferations, differentiation and fusion, and then examine the effects of acutely 
activating the CA-FoxO1 fusion protein in mature myotubes by addition of 4-OH TAM [herein 
referred to as CA-FoxO1 (+) and CA-FoxO1 (-) indicative of the presence or absence of 4-OH 
TAM treatment, respectively]. As shown in Figure 5.1, activation of FoxO1 with 4-OH TAM 
treatment [CAFoxO1 (+)] resulted in marked elevation in the mRNA of the atrogene MAFbx at 
8, 12, and 24 h, consistent with previous studies indicating that MAFbx is a direct target of FoxO 
action (Sandri et al., 2004; Stitt et al., 2004). I also noted marked elevation in the mRNA 
abundance of eIF4E-BP1 at 8, 12 and 24 h post activation (Figure 5.2). A progressive reduction 
in the mRNA expression of Raptor also was noted at later time points (12 and 24 h) (Figure 5.3). 
No changes were observed in the mRNA of eIF4E (Figure 5.4). These results show that eIF4E-
BP1 and Raptor, like MAFbx, are transcriptionally regulated by activation of FoxO1 in muscle 
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cells. These changes were not observed in CA-FoxO cells in the absence of 4-OH TAM or in 
control C2C12 cells stably transfected with empty vector (pBABE) or cells expressing 
transcriptionally inactive FoxO (FOXO- 215) irrespective of 4-OH TAM treatment. 
 
FoxO1 promotes hypo-phosphorylation of eIF4E-BP1 and increased binding 
of eIF4E-BP1 with eIF4E 
In the absence of insulin or growth factors, eIF4E-BP1 is hypophosphorylated and eIF4E-BP1 
association with eIF4E serves to repress translation. When phosphorylated, eIF4E-BP1 
dissociates from eIF4E and allows translation initiation (Schalm et al., 2003; Rhoads et al., 
1999). To examine effects of FoxO1 activation on protein synthesis, myocytes were 
differentiated to myotubes via 4 day serum withdrawal, then stimulated with 10% serum to 
promote anabolism and treated with/without 4-OH TAM. No differences were observed in eIF4E 
protein abundance when comparing the conditions (Figure 5.5). Despite the fact that the 
myotubes were serum-treated, activation of CA-FoxO1 increased eIF4E-BP1 total protein, while 
phosphorylation at the regulatory sites (Thr 37/46) was decreased at 8 h and thereafter when 
comparing CA-FoxO1 (+) with other conditions (Figure 5.6). These findings were observed in 
the absence of any differences in either Akt total protein abundance or phosphorylation of Akt 
(Ser473) (Appendix 2). Next, to test whether the hypophosphorylation of eIF4E-BP1 was 
associated with increased eIF4E association to eIF4E-BP1, immunoprecipitation analyses were 
performed on cells expressing CA-FoxO1 or FoxO1-215 proteins treated with/without 4-OH 
TAM for 12 h. Consistent with our data showing that FoxO1 results in hypophosphorylation of 
eIF4E-BP1, CAFoxO1 (+) cells displayed a markedly increased eIF4E-BP1 associated eIF4E 
after 12 h (Figure 5.7). 
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FoxO1 decreases Raptor and mTOR protein abundance, mTOR 
phosphorylation and mTOR associated Raptor 
Since FoxO1 was associated with hypophosphorylation of eIF4E-BP1, I next examined its effect 
on components of mTOR signaling. A marked reduction in the abundance of both Raptor (23% 
decrease; Figure 5.8) and mTOR (12% decrease; Figure 5.9) protein was observed at 8 h and 
thereafter, despite cells being maintained in the presence of serum and nutrients, and in the 
absence of any changes in phosphorylation of Akt (Western blots analysis of Akt can be seen in 
Appendix 2). Changes in Raptor protein levels (Figure 5.8 at 8 h precede effects of FoxO1 
activation on mRNA abundance (Figure 5.3), indicating that FoxO1 also may exert effects on 
raptor and mTOR protein expression at the post-transcriptional level. We next examined the 
phosphorylation of mTOR (Ser2448) and showed that activation of FoxO1 markedly reduces 
mTOR phosphorylation after 12 h (Figure 5.9). In the absence of nutrients, a tight association 
between mTOR and Raptor prevents the access of mTOR to its targets (Hara et al., 2004), and 
the association of mTOR and Raptor is thought to be critical for effective signaling to 
downstream targets, including eIF4E-BP and p70S6K. Accordingly, mTOR associated Raptor 
was assessed via immunoprecipitation. As shown in Figure 5.10, activation of CA-FoxO1 results 
in a marked reduction in the formation of a complex between mTOR and Raptor that would be 
expected to limit signaling to downstream targets. 
 
FoxO1 does not alter p70S6K abundance but decreases phosphorylation of 
p70S6K and impairs protein synthesis in skeletal muscle myotubes 
In addition to eIF4E-BP1, p70S6K is also a major target of the Raptor/mTOR signaling complex 
(Hara et al., 2002). Since both the phosphorylation of mTOR and the association of mTOR with 
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Raptor were reduced by FoxO1, we next examined the effect of FoxO1 activation on p70S6K. 
We observed no differences in the total abundance of p70S6K protein when comparing CA-
FoxO1 (+) with other conditions (Figure 5.11). However, phosphorylation of p70S6K on its 
regulatory residue (Thr389) was markedly reduced in CA-FoxO1 (+) cells at 8, 12 and 24 h 
(Figure 5.11).  This indicates that activation of FoxO1 not only induces changes in the expression 
of mTOR and Raptor, but also impacts upon the ability to phosphorylate and therefore propagate 
signaling to downstream targets. Since the phosphorylation of p70S6K and 4EBP-1 both play a 
critical role in promoting protein synthesis (Fingar et al., 2002), I next examined whether FoxO1 
may impair protein anabolism. As shown in Figure 5.12, the incorporation of [14C] 
phenylalanine into protein is impaired in CA-FoxO1(+) cells at 8, 12 and 24 h. In contrast, I 
observed no change in 14C incorporation in CA-FoxO1 myotubes treated with carrier alone or in 
control (pBABE) or FoxO1- 215 cells treated with 4-OH TAM. 
 
Effects of constitutively active FoxO1 on eIF4E-BP1, and mTOR signaling in-
vitro were observed in FoxO1++/+ mice 
Kamei et al., (2004) have previously observed that muscle mass is markedly reduced in 
transgenic mice expressing constitutively active FoxO1 in skeletal muscle (FoxO1++/+). While it 
is known that FoxO1 promotes catabolism, the in-vitro data presented in this chapter suggested 
that it also impairs anabolism via effects on eIF4E-BP1, and mTOR signaling. I was fortunate to 
obtain the transgenic mice from Professor Kamei and colleagues and next examined the muscles 
from FoxO1++/+ mice relative to littermate control mice (herein refereed to as WT) to see if FoxO 
exerts similar anti-anabolic effects in-vivo. At the mRNA level I showed that like our CA-FoxO1 
(+) myotubes, FoxO1++/+ mice displayed increased MAFbx (Figure 5.13) and eIF4E-BP1 
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expression (Figure 5.14), but decreased Raptor (Figure 5.15) expression. Consistent with my in-
vitro analyses, eIF4E mRNA abundance was not different when comparing FoxO1++/+ mice with 
WT (Figure 5.16). I next assessed the total and phosphoprotein abundance in FoxO++/+ and WT 
mice. As can be seen in Figure 5.17, the muscles from the transgenic mice were much smaller 
and paler in color, as reported previously (Kamei et al., 2004). The nuclear abundance of FoxO1 
was markedly higher in the FoxO1++/+ mice (Figure 5.18). Consistent with my in-vitro data, the 
FoxO1++/+ mice exhibit decreased Raptor and mTOR protein abundance and decreased mTOR 
phosphorylation (Ser2448) as well as increased eIF4E-BP1 protein abundance and decreased 
eIF4E-BP1 phosphorylation (Thr37,46) in the presence of unchanged total or phoshorylated Akt 
(Ser473). These changes were accompanied by a reduction in the phosphorylation of p70S6K on 
its regulatory residue (Ser389). Together, these data suggest that the reduction in muscle mass 
associated with FoxO1++/+ mice is due to impaired anabolic signaling as well as up-regulated 
signaling through muscle specific E-3 ligases such as MAFbx (atrogin 1). 
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Figure 5.1. Atrogin-1 (MAFbx) mRNA expression in murine C2C12 skeletal 
muscle myotubes stably expressing various FoxO1 constructs. The mRNA 
abundance of MAFbx (Atrogin 1) in C2C12 wildtype (pBABE), dominant 
negative (FoxO1-215) or constitutively active (CA-FoxO1) myotubes with a 
mutation of the ligand-binding domain of the estrogen receptor of the expression 
vector such that it specifically responds to hydroxytamoxifen (4-OH TAM). (+) 
indicates treatment with 4-OH TAM, (-) indicates treatment with vehicle for 0 h 
(filled bars), 8 h (dark gray bars), 12 h (light gray bars) and 24 h (open bars). * 
indicates difference (P<0.05) compared with 0 h. 
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Figure 5.2.  eIF4E-BP1 (4E-BP1) mRNA expression  in murine  C2C12 skeletal 
muscle myotubes stably expressing  various FoxO1 constructs. The mRNA 
abundance of eIF4E-BP1 in C2C12 wildtype (pBABE), dominant negative (FoxO1-
215) or constitutively active (CA-FoxO1) myotubes with a mutation of the ligand-
binding domain of the estrogen receptor of the expression vector such that it specifically 
responds to hydroxytamoxifen (4-OH TAM). (+) indicates treatment with 4-OH TAM, 
(-) indicates treatment with vehicle for 0 h (filled bars), 8 h (dark gray bars), 12 h (light 
gray bars) and 24 h (open bars). * indicates difference (P<0.05) compared with 0 h. 
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Figure 5.3 . Raptor mRNA expression in murine C2C12 skeletal muscle myotubes 
stably expressing various FoxO1 constructs. The mRNA abundance of  Raptor in 
C2C12 wildtype (pBABE), dominant negative (FoxO1-215) or constitutively active (CA-
FoxO1) myotubes with a mutation of the ligand-binding domain of the estrogen receptor of 
the expression vector such that it specifically responds to hydroxytamoxifen (4-OH TAM). 
(+) indicates treatment with 4-OH TAM, (-) indicates treatment with vehicle for 0 h (filled 
bars), 8 h (dark gray bars), 12 h (light gray bars) and 24 h (open bars). * indicates 
difference (P<0.05) compared with 0 h. 
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Figure 5.4. eIF4E mRNA expression in murine  C2C12 skeletal muscle 
myotubes stably expressing  various FoxO1 constructs. The mRNA 
abundance of eIF4E in C2C12 wildtype (pBABE), dominant negative (FoxO1-
215) or constitutively active (CA-FoxO1) myotubes with a mutation of the 
ligand-binding domain of the estrogen receptor of the expression vector such that 
it specifically responds to hydroxytamoxifen (4-OH TAM). (+) indicates 
treatment with 4-OH TAM, (-) indicates treatment with vehicle for 0 h (filled 
bars), 8 h (dark gray bars), 12 h (light gray bars) and 24 h (open bars). No 
significant differences detected (P<0.05) compared with 0 h. 
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Figure 5.5.  eIF4E total protein abundance in murine  
C2C12 skeletal muscle myotubes stably expressing  
various FoxO1 constructs. Total eIF4E protein in C2C12 wildtype 
(pBABE), dominant negative (FoxO1-215) or constitutively active (CA-
FoxO1) myotubes treated with 4-OH TAM (+) or without [vehicle] (- ). 
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Figure 5.6. 4E-BP1 (eIF4E-BP1) total & phospho-protein abundance in murine 
C2C12 skeletal muscle myotubes stably  expressing various FoxO1 constructs. 
Total and Phosphorylated (Thr37/46)  eIF4E-BP1 in C2C12 wildtype (pBABE), 
dominant negative (FoxO1-215) or constitutively active (CA-FoxO1) treated with (+) 
or without (- ) 4-OH TAM. * Denotes significant difference (P <0.05) compared with 
0h. 
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Figure 5.7. 4E-BP1 (eIF4E-BP1) associated (immuno-preciptated) eIF4E 
in  murine C2C12 skeletal muscle myotubes stably expressing various 
FoxO1 constructs. eIF4E-BP1 associated eIF4E in dominant negative 
(FoxO1-215) or constitutively active (CA-FoxO1) C2C12 cells treated with (+) 
or without (- ) 4-OH TAM. * Denotes significant difference (P <0.05) 
compared with 0h. 
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Figure 5.8. Raptor total protein abundance in murine C2C12 
skeletal muscle myotubes stably expressing  various FoxO1 
constructs. Total Raptor protein abundance in C2C12 wildtype 
(pBABE), dominant negative (FoxO1-215) or constitutively active 
(CAFoxO1) myotubes  treated with (+) or without (-) 4-OH TAM. * 
Denotes significant difference (P <0.05) comnpared with 0h. 
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Figure 5.9. mTOR total and phospho protein abundance in murine C2C12 skeletal 
muscle myotubes stably expressing various FoxO1 constructs. Total  and 
phosphorylated (Ser 2448) mTOR protein abundance in C2C12 wildtype (pBABE), 
dominant negative (FoxO1-215) or constitutively active (CAFoxO1) myotubes as described 
in treated with (+) or without (-) 4-OH TAM. * Denotes significant difference (P <0.05) 
compared with 0h. 
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Figure 5.10.  mTOR associated (immunoprecipitated) Raptor abundance 
in murine C2C12 skeletal muscle myotubes stably expressing various 
FoxO1 constructs. mTOR associated Raptor abundance in dominant negative 
(FoxO1-215) or constitutively active (CA-FoxO1) C2C12 cells treated with (+) 
or without (- ) 4-OH TAM. * Denotes significant difference (P <0.05) 
compared with 0h. 
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Figure 5.11.  p70 S6K1 total and phospho protein abundance in murine 
C2C12 skeletal muscle myotubes stably expressing various FoxO1 
constructs. Total  and phosphorylated (Thr 389) p70S6K protein abundance in 
C2C12 wildtype (pBABE), dominant negative (FoxO1-215) or constitutively 
active (CA-FoxO1) myotubes treated with (+) or without (-) 4-OH TAM. * 
Denotes significant difference (P <0.05) compared with 0h. 
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Figure 5.12. 
14
C-Phenylalnine incorporation (measure of protein synthesis) in murine 
C2C12 skeletal muscle myotubes stably expressing various FoxO1 constructs. 14 C 
phenylalanine incorporation in C2C12 wildtype (pBABE), dominant negative (FoxO1-215) 
or constitutively active (CA-FoxO1) myotubes. (+) indicates treatment with 4-OH TAM, (-) 
indicates treatment with vehicle. * Denotes significant difference (P<0.05) compared with 
0h. 
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Figure 5.13.  MAFbx (Atrogin-1) mRNA expression in skeletal muscle  of wildtype 
and FoxO 
++/+
 transgenic mice. The mRNA abundance of MAFbx in gastrocnemius 
muscles from transgenic mice that specifically overexpress FoxO1 in skeletal muscle 
(FoxO1 ++/+) and littermate control mice (WT). * indicates difference (P<0.05) compared 
with WT mice. 
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Figure 5.14.  4E-BP1 (eIF4E-bp1) mRNA expression in skeletal muscle of 
wildtype and FoxO 
++/+
 transgenic mice. The mRNA abundance eIF4E-BP1 in 
gastrocnemius muscles from transgenic mice that specifically overexpress 
FoxO1 in skeletal muscle (FoxO1 ++/+) and littermate control mice (WT). * 
indicates difference (P<0.05) compared with WT mice. 
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Figure  5.15   Raptor mRNA expression in skeletal muscle of wildtype and FoxO 
++/+
 
transgenic mice. The mRNA abundance of Raptor in gastrocnemius muscles from 
transgenic mice that specifically overexpress FoxO1 in skeletal muscle (FoxO1 ++/+) and 
littermate control mice (WT). * indicates difference (P<0.05) compared with WT mice. 
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Figure 5.16 . eIF4E mRNA mRNA expression in skeletal muscle of wildtype and 
FoxO 
++/+
 transgenic mice. The mRNA abundance of MAFbx in gastrocnemius muscles 
from transgenic mice that specifically overexpress FoxO1 in skeletal muscle (FoxO1 ++/+) 
and littermate control mice (WT). No significant differences detected (P<0.05) compared 
with WT mice. 
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Figure 5.17. Gross appearance (A) of wild-type and FoxO1 
++/+
 
transgenic mouse muscle. Nuclear FoxO1 abundance (relative to 
Histone 1)  and total and or phosphorylation of mTOR, Raptor, 
eIF4E-BP1,  p70S6K and Akt when comparing FoxO1
++/+
 with WT 
mice (B). Dissected gastrocnemius and soleus muscles (indicated by *) 
from (FoxO1 ++/+ mice) are smaller and paler than littermate control mice 
(WT) (A). Nuclear FoxO1 abundance (relative to Histone 1) and total and 
or phosphorylated mTOR, Raptor, eIF4E-BP1, p70S6K and Akt when 
comparing FoxO1 ++/+  with WT mice (B). 
B 
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DISCUSSION 
 
Skeletal muscle atrophy is a hallmark feature of various diseases including cancer, sepsis, HIV 
and diabetes (Price 2003). An understanding of the molecular, cellular events that regulate 
decreases in cell size is important if we are to target the atrophy observed in skeletal muscle that 
is associated with these diseases. At the present time, it is difficult to discern whether if skeletal 
muscle atrophy is a cause (aetiologically) or consequence (sequelae) of these syndromes. 
 
The molecular signals that regulate the induction of translations/initiation complexes have 
already been determined. The main objective of this chapter was thus to determine if components 
of the mTOR pathway, and by virtue of association, components of the translation/initiation 
pathway, are to some extent regulated by FoxO proteins. Investigation and experimental testing 
of this hypothesis was valid given that it is now well known that FoxO proteins promote the 
induction of genes associated with ubiquitination (Stitt et al 2004; Sandri et al 2004).  
 
FoxO proteins are conserved across species and cell type. Important reports in the literature have 
suggested that in lower order organisms (C. elegans & Drosophila) FoxO proteins regulate the 
relative expression and/or abundance of components of the mTOR pathway. They do this in two 
ways: 1) repression, and 2) by promotion of proteins involved in the translation/initiation 
pathways that either sit upstream or downstream of mTOR respectively.  
 
Jia et al. (2004) were the first authors to provide evidence that FoxO (DAF 16) repressed the 
expression of Raptor (DAF 15). The data contained in this chapter confirmed a role for FoxO1 in 
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inhibition of translation/initiation. In this regard, the data suggested that Raptor abundance is 
repressed via forced expression of FoxO in-vitro and in-vivo in a mammalian system and 
confirmed previous findings in C. elegans (Jai et al., 2004). In addition, the findings suggest that 
eIF4E-BP1 abundance is increased via forced expression of FoxO1 in-vitro and in-vivo supports 
those data published by Junger et al. (2003) and Teleman et al. (2005a; 2005b) in Drosophila.  
 
An interesting observation arising from this chapter is that related to data obtained for the 
incorporation of the 14C phenylalanine. Here I describe a situation where atrophic stimuli are 
imposed via activation of FoxO1 with a concomitant decrease in incorporation of 14C-
phenyalanine into protein. The atrophy of skeletal muscle generally observed following disuse or 
denervation is brought about by decreases in protein synthesis, but within a context of normal 
rate of protein degradation (Ferrando et al., 1996). The model used in this chapter indicates that 
within the context of FoxO1 induced atrophy, protein synthesis is reduced in the absence of 
disuse, unloading or denervation. Furthermore, this decreased synthesis is observed within a 
context of degradation of proteins (mTOR and Raptor) whose activity is to promote protein 
synthesis. This is important because it suggests that FoxO1 may be an important therapeutic 
target in diseases where overt muscle wasting occurs in the absence of disuse and unloading. 
 
Previous findings by Bastie et al. (2004) using a similar in-vitro model to the one described in 
this chapter and another study by Giannakou et al. (2004) suggested that the forced expression of 
FoxO in Drosophila increased the storage of lipid in the ‘fat body’ of these animals. The 
Drosophila fat body is a storage depot for lipid that is utilised during times of starvation. Bastie 
et al. (2004) showed that forced expression of FoxO in C2C12 murine skeletal muscle cells 
induces the expression of FAT/CD36 a lipid transporter whilst increasing the deposition of lipid 
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in these cells. Taken together, the data of Bastie et al. (2004) and those data presented in this 
chapter, further support the notion that the biological activity of FoxO proteins is conserved 
across species types. Schematic interpretation of these results figure 5.18. 
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Figure 5.18. Schematic representation of regulation of mTOR activity and 
protein anabolism by FoxO proteins. 
 
Under conditions of nutrient and growth factor activity (left panel), Akt phosphorylates and 
inactivates FoxO proteins. Akt also phosphorylates tuberous sclerosis complex (TSC) 
proteins, allowing Rheb to phosphorylate and activate mTOR. mTOR phosphorylates 
eIF4EBP-1 (4EBP), allowing eIF4E to bind EIF4G and promote translation initiation of 
capped mRNAs. mTOR also phosphorylates p70S6K, which also promotes translation of 
protein. Transcriptionally active FoxO proteins stimulate the expression of eIF4E-BP1 (4E-
BP) which displaces eIF4G from eIF4E. FoxO proteins also suppress the expression of Raptor 
and mTOR, limiting the phosphorylation of 4EBP proteins and p70S6 kinase, and protein 
synthesis. Under conditions when nutrients are depleted and insulin and growth factor levels 
are low (right panel), Rheb is sequestered with TSC proteins, while FoxO proteins are active. 
FoxO proteins promote the expression of eIF4EBP-1 and suppresses the expression of Raptor 
and mTOR, resulting in reduced phosphorylation of p70S6K, sequestration of eIF4E in an 
inactive complex, and impaired anabolism.  
 
Adapted from Southgate et al., (2006). 
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CHAPTER 6  
INTRODUCTION 
 
Increases in circulating Tumor Necrosis Factor-alpha (TNF-α also called cachectin), an 
endotoxin induced serum factor (Carswell et al., 1975) have been reported to be highly associated 
with type 2 diabetes and insulin resistance (Zinman et al., 1999; Saghizadeh et al., 1996; Kern et 
al., 2001). 
 
The muscle wasting observed in AIDS (Chang et al., 1998), cachectic cancer patients (Baracos et 
al., 2000) as well as normal aging (Grounds 2002; Carter et al., 2001) are closely associated with 
the expression of TNF-α. TNF-α can interfere with muscle growth and regeneration, in part by 
disrupting both (Insulin-like-growth-factor-1) IGF-1 (Frost et al., 1997) and insulin signaling 
cascades (Uysal et al., 1997; Hirosumi et al., 2002).  
 
Interestingly, Alikhani et al. (2005) recently reported that TNF-α induced nucleic localisation 
and subsequent activation of FoxO1 target genes in-vitro and in-vivo. Using primary dermal 
fibroblasts and mice inoculated with human recombinant TNF-α these authors discovered that 
FoxO1 functions as a ‘master switch’ that regulates gene expression necessary for TNF-α 
induced fibroblast apoptosis (Alikhani et al., 2005) Two recent reports (Stitt et al., 2004; Sandri 
et al., 2004) have provided evidence that the glucocorticoid, dexamethasone, induces the nucleic 
localisation of FoxO1 and this nucleic localisation results in the up regulation of MAFbx.  Li et 
al. (2005) report that treatment of C2C12 myotubes with TNF-α induces the transcription of 
MAFbx (atrogin-1) in a p38 MAPK dependant manner. These authors did not attempt to 
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investigate the cellular localisation of FoxO1 in their experiments, but did suggested that in later 
studies that it would be wise to do so given the reports by Sandri et al. (2004) and Stitt et al. 
(2004) who provided evidence that MAFbx was a bone fide target of FoxO transactivation. Stitt 
et al. (2004), Sandri et al. (2004) and Alikhani et al. (2005) suggest that both glucocorticoid and 
pro-inflammatory cytokines mediate FoxO target gene expression. 
 
Given the data detailed in Chapters 2, 3, and 4 suggested that FoxO1 exhibits a predominantly 
nucleic localisation in diabetic subjects (Chapter 2) and experimentally induced insulin resistance 
(Chapters 3 and 4), it was deemed appropriate to investigate other ‘diabetogenic’ compounds that 
might impact upon growth factor mediated re-localisation of FoxO1. Using exogenous 
compounds to impact upon growth factor mediated translocation of FoxO1 appeared a logical 
progression given the data from Chapter 3 suggested fatty acids can perturb this process. The 
main rationale for conducting the experiments detailed in this Chapter was to assess if TNF-α 
reduces the ability of IGF-1 to induce cytosolic sequestration of FoxO1 and compare this to 
regimes (starvation and glucocorticoid stimulation) that are known to impact upon FoxO 
localisation.  
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METHODS 
 
Mouse C2C12 myoblasts were seeded and grown in proliferation media (DMEM, 10% FBS, 1% 
Penstrep) to confluence. When approximately 70% confluent, myoblasts were trypsinated and 
sub-cultured onto clambered glass slides. The glass slides were pre-coated with 0.2% gelatin in 
order to assist in myoblast attachment. When the subcultures had reached approximately 70% 
confluence, the myoblast cultures were transfected with eGFP-FoxO1 (a kind gift from Professor 
Terry Unterman, University of Chicago) plasmid DNA using lipofectamine according to the 
manufacture’s instructions.  After the cells were incubated for 24 h in media containing the 
plasmid DNA, the media were replaced and the cells allowed to recover for 12 h. Following 
recovery, the cells were treated with TNF-α (20ng/ml [Sigma]) or dexamethasone (100 nM) for 8 
h in the presence of 10% FBS. Following the 8 h treatment incubations, the appropriate cell 
cultures were stimulated with 10ng/ml R3- IGF-1 (a potent IGF-1 analogue [Sigma]) for 30 min. 
 
Following cessation of cell treatments, myoblasts were fixed in 4% paraformaldehyde, washed 4 
times with 1X PBS. Fixed culture slides were incubated with an aqueous fixative containing 
DAPI to stain the nuclei and viewed with a laser confocal microscope.  
 
Isolation of nucleic fractions and western blot analysis of FoxO1 nucleic protein in wild-type 
C2C12s treated with dexamethasone/TNF-α/serum/IGF-1 was undertaken as described in 
Chapter 3. 
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RESULTS 
 
Confocal microscopy images of C2C12 myoblasts (Figure 6.1, Panel [A]) indicate that in the 
starved state GFP-FoxO1 is predominantly nucleic, whereas in the fed state (serum fed), GFP-
FoxO1 is predominantly cytosolic. Treatment of serum starved GFP-FoxO1 myoblasts with IGF-
1 induced localisation of the GFP protein to the cytosol, a situation comparable to the fed state. 
These results suggest that serum treatment (the fed state) is sufficient to exclude GFP-FoxO1 
from the nucleus and moreover, IGF-1 has the same propensity to result in cytosolic re-
localisation following serum starvation. In non-transfected C2C12 myoblasts, endogenous FoxO1 
is predominantly nucleic in the fed state, but treatment with IGF-1 following serum withdrawal 
results in nucleic exclusion (Fig 6.1, Panel [B]). 
 
Confocal microscopy images of C2C12 myoblasts maintained in the fed state (serum fed) and 
then treated with dexamethasone (Figure 6.2 Panel [A]) for 8 h indicated that dexamethasone 
induces a ‘starved like’ effect, as GFP-FoxO1 becomes predominantly nucleic. This situation was 
not reversed by the addition of IGF-1, suggesting that dexamethasone is a potent inhibitor of 
FoxO1 cytosolic sequestration. In non-transfected C2C12 myoblasts, endogenous FoxO1 was 
predominantly nucleic in the fed state when treated with dexamethasone, and IGF-1 failed to 
induce cytosolic sequestration in the presence of serum and dexamethasone (Figure 6.2, Panel 
[B]). 
 
Confocal microscopy images of C2C12 myoblasts maintained in the fed state (serum fed) and 
then treated with TNF-α  (Figure 6.3 Panel [A]) for 8 h indicated that TNF-α induces a ‘starved 
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like’ effect similar to dexamethasone, as GFP-FoxO1 becomes predominantly nucleic. This 
situation is not reversed by the addition of IGF-1, suggesting that TNF-α is a potent inhibitor of 
FoxO1 cytosolic sequestration. In non-transfected C2C12 myoblasts, endogenous FoxO1 is 
predominantly nucleic in the fed state when treated with TNF-α, and moreover, IGF-1 failed to 
induce cytosolic sequestration in the presence of serum and TNF-α  (Fig 6.3, Panel [B]). 
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Figure 6.1. (A) C2C12 myoblast transfected with wildtype GFP-FoxO1 
then starved (serum free), fed (+ serum) or starved and treated with 
IGF-1 (Starved + IGF). (B) Nucleic abundance of FoxO1 in wildtype 
C2C12 myoblasts after serum starved conditions or serum starved 
conditions + IGF-1. 
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Figure 6.2. (A) C2C12 myoblast transfected with wildtype GFP-FoxO1 
maintained in the fed state and treated with dexamethasone or  
dexamethasone + IGF-1. (B) Nucleic abundance of FoxO1 in  wildtype 
C2C12 myoblasts maintained in the fed state and treated  with 
dexamethasone or dexamethasone + IGF-1. 
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Figure 6.3. (A) C2C12 myoblast transfected with wildtype GFP-FoxO1 
maintained in the fed state and treated with TNF-α or  TNF-α  + IGF-1. 
(B) Nucleic abundance of FoxO1 in  wildtype C2C12 myoblasts 
maintained in the fed state and treated with TNF-α  or TNF-α  + IGF-1. 
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DISCUSSION 
 
Imaging of C2C12 myoblasts using confocal microscopy, revealed that serum starvation induces 
a marked re-localisation of GFP-FoxO1 and the growth factor IGF-1 has the ability to re-localise 
GFP-FoxO1 to the cytosol to the same degree as serum. In agreement with both Stitt et al. (2004) 
and Sandri et al. (2004) the glucocorticoid, dexamethasone, induced a ‘starved-like’ effect on 
GFP-FoxO1 and stimulation with IGF-1 failed to re-localise GFP-FoxO1 to the cytosol. Alikhani 
et al. (2005) indicated that FoxO1 functions as a ‘master switch’ that regulates genes associated 
with fibroblast apoptosis in response to TNF-α stimulation. The confocal images presented 
support the Eletromobility Shift Assay (EMSA) data of Alikhani et al. (2005) with regard to 
FoxO1 localisation after stimulation with TNF-α. 
 
It is noteworthy that the nucleic localisation of endogenous FoxO1 as evidenced by western blot 
analysis of wild-type (non transfected) C2C12 myoblasts mirrors the response seen with the 
GFP-FoxO1 construct; i.e. when wild-type C2C12 myoblasts were treated with dexamethasone 
and TNF-α a starved like localisation was observed, indicating that FoxO1 was distributed 
predominantly in the nucleus. Similar to the results with GFP-FoxO1 myoblasts, IGF-1 failed to 
result in cytosolic sequestration of the protein suggesting that this is a bone fide response by 
FoxO1 to stimulation with dexamethasone and TNF-α and not simply an artifact associated with 
the GFP-FoxO1 utilisation. 
 
Increases in glucocorticoid and TNF-α are known to induce muscle wasting and cachexia (Frost 
et al., 1997;Uysal et al., 1997; Hirosumi et al., 2002). Glucocorticoids are potent antagonists of 
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insulin action and, when in excess can promote insulin resistance and obesity (Brindley 1995). 
Increases in circulating TNF-α have been reported to be highly associated with Type 2 diabetes 
and insulin resistance (Zinman et al., 1999; Saghizadeh et al., 1996; Kern et al., 2001). Both 
glucocorticoids and TNF-α have been reported to promote insulin resistance via their ability to 
impact upon activation (phosphorylation) of Akt (Zinman et al., 1999; Saghizadeh et al., 1996; 
Frost et al., 1997;Uysal et al., 1997; Hirosumi et al., 2002). FoxO1 is a substrate of Akt and its 
transcriptional activity is negatively regulated via the activity of Akt (Biggs et al., 1999; Brunet 
et al., 1999; Guo et al., 1999; Kops et al., 1999; Nakae et al., 1999; Rena et al., 1999; Takaishi et 
al., 1999; Tang et al., 1999; Zhang et al., 2002). Given the results described here, it is reasonable 
to assume that the negative effects of dexamethasone and TNF-α on skeletal muscle function and 
insulin sensitivity could be mediated via their shared ability to promote FoxO1 nuclear 
localisation. Moreover, given the localisation of FoxO1 is nucleic in the presence of 
dexamethasone, and similarly with TNF-α stimulation, it seems reasonable to assume that both of 
these compounds would induce similar FoxO1 target genes. Increases in transcriptionally active 
FoxO1 have been associated with the induction of the E3-Ubiquitin ligase, MAFbx (Stitt et al 
2004; Sandri et al., 2004).  Thus it is tempting to speculate that the shared ability of these 
compounds to promote FoxO1 activity, mediates their negative effects on muscle function.  This 
hypothesis remains to be tested and is beyond the scope of this thesis. However, the future 
directions (Chapter 7) discuss how this situation will be addressed. 
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CHAPTER 7 
CONCLUDING DISCUSSION &  
FUTURE DIRECTIONS 
 
The regulation of PGC-1α and downstream OxPhos genes is complex and not fully elucidated, 
particularly in skeletal muscle. It was shown from the data described in Chapters 2 and 3, that in 
both human muscle biopsy specimens and primary human skeletal muscle cell culture, insulin 
reduces the expression of PGC-1α mRNA and down-stream OxPhos genes in a FoxO1 dependant 
manner in healthy, but not insulin resistant, skeletal muscle.  
 
These data are concomitant with the observation that phosphorylation, and subsequent nuclear 
exclusion of FoxO1 is reduced in the skeletal muscle of type 2 diabetics and human primary 
skeletal muscle cultures treated with palmitic acid (experimentally induced insulin resistance), 
secondary to reduced insulin-stimulated Akt phosphorylation. Furthermore, the data presented in 
Chapters 2 and 3 demonstrated that the reduced phosphorylation and subsequent nuclear 
exclusion of FoxO1 were somewhat Akt dependent. The results presented in Chapters 2 and 3 
regarding Akt’s role in negatively regulating (ameliorating) the insulin stimulated FoxO1 target 
gene transcriptional activity, were supported by those data presented in Chapter 4, that showed 
that effect of insulin on these processes was blunted in the skeletal muscle of transgenic mice 
where Akt 2 is genetically knocked out (Akt2 −/− mice).  
 
The observation that PGC-1α and downstream genes were reduced in the skeletal muscle of 
patients with type 2 diabetes is consistent with previous studies (Patti et al., 2003; Mootha et al., 
2003). At the time of writing, no previous studies have examined the mRNA expression of 
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COX4, FoxO1, or PSARL in the skeletal muscle of Type 2 diabetes. The mRNA analyses 
presented in Chapter 2 demonstrate that COX4 was reduced (P<0.05), while FoxO1 (P=0.10) and 
PSARL (P=0.16) mRNA tended to be lower in the Type 2 diabetic patient group. COX4, a 
nuclear gene encoding part of complex IV in mitochondrial respiration, was recently shown to be 
increased by PGC-1α over-expression in mice (Lin et al., 2002) and by aerobic training in elderly 
subjects (Short et al., 2003). In this latter study, however, this increase did not translate to 
increased insulin sensitivity (Short et al., 2003).   
 
Only one previous preliminary study, (published only in abstract form), has examined the effect 
of palmitate treatment on OxPhos gene expression. Crunkhorn et al. (2004) showed that both 
PGC-1α and NRF-1 were markedly reduced by palmitate in the C2C12 muscle cell line. The 
results presented in Chapter 3 were consistent with this previous observation and suggested that 
even acute insulin resistance, as induced by 12 hours of palmitate treatment, reduced the mRNA 
of PGC-1α, the hierarchical regulator of OxPhos gene expression.  
 
A major finding from the studies described in this thesis is that while insulin repressed PGC-1α 
and downstream OxPhos mRNA expression in healthy skeletal muscle, it did not do so in the 
muscles of patients with type 2 diabetes nor in experimentally induced insulin resistance. The 
effect of insulin on OxPhos gene expression in skeletal muscle is controversial, since insulin 
either increases PGC-1α in young and elderly subjects (Ling et al., 2004) or decreases PGC-1α in 
C2C12 cells (Crunkhorn et al., 2004). In addition, both ND1 and COX1 mRNA have been shown 
to be increased in patients by insulin stimulation (Huang et al., 1999), while the mRNA encoding 
COX4 and ND4 is increased by 8 h, but not by 4 h, of high dose insulin stimulation (plasma 
insulin ~350 pmol·l−1) in healthy humans (Stump et al., 2003). Although not significant, 4 h low 
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dose insulin (plasma insulin ~50 pmol·l−1) tended to repress COX3 and COX4 mRNA (Stump et 
al., 2003). With regard to data presented in this thesis (Chapters 2, 3 and 4), the results were very 
consistent irrespective of the model investigated when using PGC-1α mRNA as a readout. 
Notwithstanding the fact that cell culture experiments and rodent experiments are very different 
from the human in-vivo model, and palmitate treatment is only one model to induce cellular 
insulin resistance in-vitro, insulin significantly repressed PGC-1α mRNA expression in the 
controls of all models studied; those being healthy human muscle biopsy specimens, cultured 
human primary myotubes and muscle biopsy specimens from wild type mice. In addition, in the 
in-vivo study COX4 and NRF-1 were also repressed by insulin treatment. In contrast, in the 
insulin resistant state, insulin did not repress mRNA expression of these OxPhos genes either in-
vivo or in-vitro.  
 
One potential confounding variable related to the human in-vivo study was that the fasting 
glucose in type 2 (9.1 mM) was allowed to fall to 5.0 mM before we maintained euglycaemia at 
this concentration. Although we are unable to assess the effect of this lowered level of glycaemia 
in the patients with Type 2 diabetes, it cannot be ruled out that this possibly affected our 
measurements. 
 
In a previous study that measured and reported a small increase in PGC-1α mRNA with insulin, 
no attempt was made to explain why insulin would promote expression of this gene (Ling et al., 
2004). However, given that Akt phosphorylates FoxO1 to down-regulate PGC-1α promoter 
activity in both HEPG2 cells (Daitoku et al., 2003) and 293T cells (Matsuzaki et al., 2003) when 
insulin stimulated, this previous result is difficult to interpret. It must be noted, however, that 
whilst the results reported here demonstrate a repression of mitochondrial gene expression by 
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insulin, it is not implied that this would result in a decrease in mitochondrial function or 
respiration. With regard to the experiments detailed in Chapter 1, I  was unable to measure 
indices of mitochondrial function such as CS, β-HAD, or MAPR after insulin treatment due to 
insufficient sample size. Therefore, it is not possible to determine from these data whether the 
repression of mRNA expression by insulin in CON or indeed the lack of repression in patients 
with Type 2 diabetes had any impact on mitochondrial function.  
 
It is well known that insulin stimulation increases respiration, as measured by limb VO2 (Kelley 
et al., 1999). In addition, Stump et al. (2003) have demonstrated marked increases in skeletal 
muscle mitochondrial ATP production rates (MAPR) with 4 h of insulin stimulation in the 
absence of any significant changes in mRNA expression of COX3, COX4, and ND4. Clearly, the 
physiological significance of FoxO1 regulation of PGC-1α mRNA expression by insulin and 
downstream physiological processes requires further research. 
 
It may appear paradoxical that patients with type 2 diabetes have impaired mitochondrial function 
(Petersen et al., 2003; Patti et al., 2003; Mootha et al., 2003; Short et al., 2003; Huang et al., 
1999; Stump et al., 2003; Kelley et al., 1999), but have a higher PGC1-α mRNA expression upon 
insulin stimulation may appear paradoxical. However, even though these patients are, in the basal 
state, relatively hyperinsulinaemic when compared with their healthy counterparts, this is not 
sufficient to chronically phosphorylate Akt (Figure 2.4) or indeed FoxO1 (Figures 2.5 and 2.6). 
Therefore, one would not expect FoxO1 to be a regulator of PGC-1α at any time other than when 
insulin is transiently increased in the immediate postprandial period. Rather, at most times, it is 
likely that other transcription factors for PGC-1α such as MEF2, NFAT, and CREB play a greater 
role than FoxO1 in regulating PGC-1α. Since inactivity would reduce the signals to these 
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transcription factors, it appears that these factors are overall quantitatively more important in 
regulating PGC-1α. It is also clear that these factors may also be influenced by fatty acids 
because in the basal state treating muscle cells in-vitro with palmitate reduces PGC-1α mRNA 
(Figure 3.2) but at the same time reduced FoxO1 phosphorylation at Ser256 (Figure 3.4). It also 
appears that these factors may play a role in regulating PGC-1α in the Akt2−/− mice, since, in the 
basal state, FoxO1 phosphorylation or nuclear abundance was not different (Figs 4.2b, 4.3a & 
4.3b respectively) and yet PGC-1α mRNA was reduced relative to littermate control mice (Figure 
4.1).  
 
At the time of writing, this was the first study to measure the effect of insulin on phosphorylation 
and subsequent nuclear exclusion of FoxO1 and the role of Akt in this process in the skeletal 
muscle of type 2 diabetics or experimental models of insulin resistance. Insulin-stimulated Akt 
phosphorylation was reduced in the muscle of type 2 diabetics and skeletal muscle myotubes 
rendered insulin resistant with palmitic acid. The reduced insulin-stimulated phosphorylation of 
FoxO1 on Ser256 in palmitate-treated myotubes (Figure 3.4) was significant in-vitro, and there 
was a strong tendency for this reduction in-vivo (figure2.5). Insulin-stimulated phosphorylation 
of FoxO1 on Thr24 was consistent both in-vivo and in-vitro (Figs 2.6 & 3.5 respectively). This 
finding suggests that the localisation of FoxO1 in the nucleus is increased in insulin resistant 
muscle and the ability of insulin to reduce FoxO1 transactivation of PGC-1α via Akt-mediated 
phosphorylation is decreased. Unfortunately, due to tissue constraints, the nuclear abundance of 
FoxO1 could not be investigated in our in-vivo human studies. However, in-vitro, we observed a 
significant decrease in the nuclear abundance of FoxO1 in insulin-stimulated vehicle-treated 
myotubes, but not in insulin stimulated palmitate pretreated myotubes (Figure 3.6), suggesting 
 135
 
that when myotubes are experimentally rendered insulin resistant, FoxO1 remains predominantly 
nuclear and retains its inherent transactivation ability.  
 
Based on in-vivo human experiments and the in-vitro cell culture experiments, I was unable to 
determine if impaired Akt phosphorylation was causally linked to the observation that FoxO1 
phosphorylation and nuclear exclusion were also impaired in insulin resistance. Hence, 
experiments were performed in Akt2 −/− mice. In wild type (littermate) control mice insulin 
phosphorylated Akt (Figure 4.2a) and FoxO1 (Figures 4.2b and 4.3a) and resulted in reduced 
nuclear abundance of this protein (Figure 4.3b). This was in contrast with data obtained from the 
Akt2−/− mice where insulin failed to sequester FoxO1 to the cytoplasm, as evidenced by the 
maintenance of FoxO1 nucleic abundance in these animals when compared with wild type 
littermate control (Figure 4.3b). Hence, these data indicate that Akt plays a central role in the 
regulation of PGC-1α mRNA expression by FoxO1 with insulin stimulation (Figure 4.4). 
Recently, Kamei et al. (2004) reported that PGC-1α mRNA levels are increased in muscle 
specific FoxO1 over-expression mice, suggesting that, as is seen in liver, FoxO1 promotes PGC-
1α gene expression in muscle. This is consistent with the data presented here, insomuch as when 
we insulin-stimulated Type 2 diabetic muscle, experimentally induced insulin resistant human 
skeletal muscle myotubes and transgenic Akt 2-/- mice, an increased PGC-1α mRNA expression 
was observed. In this regard, although FoxO1 was not over expressed in the studies described in 
Chapter 2, 3 and 4, a decreased ability to phosphorylate and therefore negate FoxO1 
transactivation of PGC-1α in the insulin resistant models was observed. 
 
The importance of intact mTOR signaling and downstream targets in linking nutritional and 
hormonal cascades to the regulation of cell size is well established (Gingras et al., 2001; Zhang et 
 136
 
al., 2005). Importantly, recent evidence suggests that eIF4E-BP1, together with p70S6K, 
regulates animal growth and/or size (Fingar et al., 2002; Miron et al., 2002).  Given the critical 
contribution that mTOR signaling affords to overall organismal growth and size and with 
consideration of the fact that evidence in the literature suggests FoxO proteins limit growth it was 
of interest to investigate if FoxO played a regulatory in the propagation of mTOR signaling. The 
data presented in Chapter 5 suggests that the induction of a constitutively active FoxO1 construct 
in C2C12 myotubes and constitutive expression of FoxO1 in the skeletal muscles of mice, results 
in increased abundance of eIF4E-BP1 mRNA and protein. The increases in eIF4E-BP1 protein 
and mRNA were concomitant with a reduction in the abundance of Raptor, an important mediator 
of mTOR pathway signaling, reduced phosphorylation of the downstream protein p70S6K, and 
associated with reduced protein synthesis as measured by incorporation of 14C phenylalanine 
into cells. These data provide compelling evidence that FoxO proteins, previously known to 
activate catabolic pathways via transcriptional activation of atrogenes such as MAFbx, also play 
an important role in negatively regulating anabolic pathways.  
 
In this regard, Raptor acts as an essential scaffold protein with mTOR (Heesom et al., 1998; 
Gingras et al., 2001) and, in the presence of growth factor and nutrients, the Raptor/mTOR 
complex phosphorylates and removes eIF4E-BP1 inhibitory binding to eIF4E. The removal of 
the inhibitory binding of eIF4E-BP to eIF4E allows the formation of the eIF4F complex 
formation and subsequent propagation of translation (Hara et al., 2002; Nojima et al., 2003). 
Interestingly, the mTOR-catalyzed phosphorylation of eIF4E-BP1 in-vitro is entirely dependant 
on the presence of Raptor (Hara et al., 2002; Nojima et al., 2003), whereas the mTOR mediated 
phosphorylation of p70S6K (another downstream target of mTOR signaling essential for 
anabolism) in-vitro is less dependant on the presence of Raptor (Nojima et al 2003). The data 
 137
 
presented in Chapter 5 support Raptors’ proposed contribution towards p70S6K phosphorylation, 
in that when Raptor abundance is reduced, p70S6K phosphorylation is reduced concomitantly, 
but not ameliorated completely. Interestingly, Ohanna et al. (2005) suggested the presence of a 
pathway, independent of mTOR, which acts in concert with p70S6K to mediate Akt induced 
growth and hypothesized that inhibition of FoxO1 could fulfill such a function. While FoxO 
proteins can exert p70S6K-independent effects on growth, the data presented here provide 
evidence that FoxO proteins also may play an important role in regulating the phosphorylation 
(and, therefore, function) of p70S6K phosphorylation (Figures. 5.12 & 5.18). A corollary of this 
finding is that inhibition of FoxO1 (and thus catabolic processes) may be important in the ability 
to increase p70S6k phosphorylation/activation (and thus promote anabolism). 
 
The data obtained in-vitro in genetically modified C2C12 myotubes were mirrored in FoxO1++/+ 
transgenic mice, suggesting that FoxO1 is a possible therapeutic target for clinical conditions 
where muscle wasting is indicated. As previously reported, FoxO1++/+ mice are characterized by 
markedly reduced muscles mass (Kamei et al., 2004). Given the well known effect of FoxO 
proteins on muscle specific E-3 ligases such as MAFbx, this skeletal muscle phenotype was 
ascribed to the up regulation of catabolic pathways. The data described in Chapter 5 demonstrate 
that FoxO1++/+ mice display markedly reduced mTOR signaling (Fig. 5.18), indicating that the 
skeletal muscle phenotype of these mice is also mediated, at least in part, by impaired anabolism. 
The exact physiological significance of the data presented here remains to be determined, but it is 
tempting to speculate that the role for FoxO1 is maybe to provide contextual growth inhibition 
For example, when nutrients and insulin/growth factors are available, FoxO1 is transcriptionally 
inactive and growth pathways predominate (see schematic Figure 5.1). Conversely, when 
nutrients are depleted and insulin/growth factor levels are low, or under circumstances where 
 138
 
insulin signaling is impaired in the presence of adequate nutrients, such as insulin resistance 
(Southgate et al., 2005), transcriptionally active FoxO proteins may function both to promote the 
function of catabolic pathways that mobilize nutrient stores, including proteolysis, and also to 
suppress the function of anabolic pathways that promote growth, including protein synthesis. 
This concept is consistent with recent studies in the liver, where FoxO1 exerts positive effects on 
the activity of metabolic pathways that are adaptive for periods of nutrient restriction (amino acid 
catabolism, glycerol transport, gluconeogenesis) and negative effects on the expression of 
pathways involved in promoting anabolism in the fed state (glycolysis, the pentose phosphate 
shunt, lipogenesis and sterol synthesis) (Zhang et al., 2005). Together, these findings suggest that 
FoxO proteins play an important role in integrating the metabolic adaptation to changes in 
nutritional status in multiple target tissues and through effects on both anabolic and catabolic 
pathways.  
 
 
Conclusion 
In conclusion, there are few studies that have examined the relationship between PGC-1α 
expression and insulin-stimulated glucose transport and/or insulin sensitivity. The data that 
constitutes a significant part of this thesis indicates that insulin decreases the expression of genes 
involved in oxidative metabolism in healthy muscle, but this does not occur in patients with type 
2 diabetes and in skeletal muscle cultures rendered insulin resistant. This is most likely due to a 
decrease in FoxO1 phosphorylation secondary to reduced Akt activity.  
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Recent data from other cell types, i.e. those other than muscle cells, suggest that PGC-1α gene 
expression is increased within a context of oxidative stress (Valle et al., 2005). This developing 
notion is intriguing as this could well be a rationale for non-repression of PGC-1α mRNA post 
insulin stimulation in our ‘diabetic’ models. In this regard, the observation described by the data 
presented in this thesis could well be ascribed to a protective effect afforded by increased PGC-
1α mRNA in the insulin stimulated context as this would provide message for mitochondrial 
biogenesis. This notion is given credence when is it is considered that oxidative stress inducing 
stimuli are well known initiators of mitochondrial damage and dissemination. 
 
In lower order organisms, FoxO1 has been to shown to limit organismal growth, a function that 
has been ascribed to FoxO’s role in the survival response initiated by growth factor withdrawal or 
nutrient deprivation respectively. Later studies from this thesis provide the first evidence that 
FoxO1 inhibits the function of protein anabolic pathways in skeletal muscle via increased 
expression and reduced phosphorylation of the translational repressor protein eIF4E-BP1 and 
impaired signaling through mTOR/Raptor complexes. FoxO1 may be an important therapeutic 
target for human diseases where anabolism is impaired.  
 
This thesis highlights some interesting observations related to the physiological role that FoxO1 
might play in mammalian skeletal muscle. FoxO proteins provide one of the major interfaces 
between the transcriptional output of insulin and other growth factors. The experimental data 
presented in Chapters 2, 3 and 4 indicate that FoxO1 cytosolic shuttling is perturbed and its 
transcriptional activity is increased in insulin resistant, diabetic models. Intact insulin signalling 
is known to decrease lifespan in lower order organisms whilst inducing increases in organismal 
size (growth). In contrast, down regulation of insulin signalling induces reductions in organismal 
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size, but those organisms that exhibit smaller size due to reduced insulin signalling also exhibit 
greater longevity. Thus, as suggested by Antebi (2004), it appears that insulin signalling is pro-
aging, whilst inhibition of the pathway prolongs life.  The data presented in Chapter 5 infers that 
the increased FoxO activity imposed by the insulin resistance described in Chapters 2, 3 and 4 
may well afford the cell increased longevity via the up regulation of growth inhibition pathways 
i.e. survival pathways predominate at the expense of growth. It would appear that the role that 
FoxO proteins play in relation to growth and longevity is dictated via their ability to be regulated. 
It seems that neither absolute inhibition nor absolute promotion of FoxO1 transcriptional activity 
favours long term probity. In this regard, if FoxO1 is predominantly inhibited, one would expect 
the cell to lose its ability to induce genes associated with stress protection. Likewise, if FoxO1 
were to be predominantly promoted, one would expect the cell to lose its ability to grow and 
develop. Thus, it is the fine tuning or regulation of FoxO1 which dictates its physiological role in 
the maintenance of cellular probity, growth and metabolism. Could it be then, that the insulin 
resistance exhibited in peripheral tissues imposes a protective effect on tissues that exhibit 
relative insulin insensitivity? This hypothesis requires further investigation. Further work 
investigating FoxO1 role in lifespan extension in the context of insulin resistance forms a 
significant part of the future directions section. 
 
 
Future Directions: autophagy 
 
Cellular homeostasis is maintained by a highly regulated balance between synthesis and 
degradation of intra-cellular components. For the most part, this balance is maintained via 
intracellular signaling cascades in response to growth factor or nutrient availability. It appears 
that similar intracellular processes are initiated in order to conserve cellular function, when 
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growth factors or nutrients are low. One such process that provides the cell with an‘endogenous 
pool’ of nutrients during holistic nutrient deprivation is termed, “autophagy”. Autophagy 
describes an evolutionary conserved lysosomal pathway involved in the turnover of long-lived 
proteins and organelles (Klionsky & Ohsumi, 1999; Seglen & Bohley, 1992), and as such 
represents a transitory, tactical response to growth factor or nutrient deprivation (Yang et al., 
2005). This notion is supported by the fact that autophagy has been shown to contribute toward 
the extension of life span induced by calorie restriction (Bergamini et al., 2004). 
 
Autophagy is initiated with the formation of a multilayer-membrane bound vacuole 
(autophagosome) that sequesters fractions of the cytoplasm (Fengsrud et al., 1995). The 
autophagosomal membrane is derived from the pre-autophagosomal structure called the 
phagophore, which is a poorly characterized intracellular organelle (Fengsrud et al., 1995). The 
autophagosome is a double-membrane structure containing undigested cytoplasmic materials 
including organelles. The outer membrane of the autopahgosome fuses with the lysosome 
membrane. Various hydrolytic enzymes are supplied to the autophagosome and the cytoplasm-
derived contents are degraded together with the inner membrane of the autophagosome. This 
degrading structure is termed the autolysosome/autophagosome (Mizushima et al., 2004). 
 
There is a potential link between autophagy and a number of diseases in humans. For example, 
cancer, cardiomyopathy and neurodegenerative disorders such as Alzheimer’s, Parkinson’s and 
Huntington’s diseases, amyotrophic lateral sclerosis and prion diseases are all associated with 
increased autophagic activity (Shintani & Klionsky 2004). 
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In summary, autophagy is characterized by sequestration of bulk cytoplasm and organelles in 
autophagic vesicles and delivery of them to the lysosome, where the materials in the vesicles are 
degraded and recycled to general nutrient stores to maintain essential cellular functions under 
starved conditions, a situation that mirrors insulin resistance and Type 2 diabetes (Klionsky et al., 
1999). 
 
Mammalian Target of Rapamycin Signaling 
The mammalian target of rapamycin (mTOR) pathway is emerging as a major contributor in the 
regulation of cellular function. Mammalian Target of Rapamycin (mTOR) proteins are protein 
kinases that were first identified in Saccharomyces cerecisiae through mutants that confer 
resistance to growth inhibition induced by the immunosuppressive macrolide rapamycin (Kunz et 
al.,1993). Interestingly, in response to growth factor (e.g. insulin) activation, Raptor forms a 
complex with mTOR and phosphorylates eukaryotic Initiation Factor 4- Binding Protein 1 
(eIF4E-BP1) (Hara et al., 2002). De-phosphorylation of eIF4E-BP1 is a limiting factor in protein 
synthesis, as a result of increased association with eIF4E. Raptor is indispensable for TOR 
signaling in-vivo (Kim et al., 2002), and is absolutely required for the mTOR-catalysed 
phosphorylation of eIF4E-BP1 in-vitro (Hara et al., 2002; Nojima et al., 2003). 
 
Insulin, mTOR and autophagy 
Insulin, one the most post potent growth factors, has been shown to negatively regulate 
autophagic vacuole formation in hepatic (liver) tissue ex-vivo (Kanazawa et al., 2004). Moreover, 
Mizushima et al., 2004 reported a marked induction of autophagy in the muscle fibers of 
transgenic animals in response to nutrient starvation (a situation that induces hypoinsulinaemia). 
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Negative regulation of autophagy by insulin, is mediated via the activation of the PI-3K/PDK-
1/Akt pathway which is thought to propagate through to the mammalian target of rapamycin 
(mTOR) pathway (Scott et al., 2004). The importance of mTOR activation in the amelioration of 
autophagy is highlighted by the data of Blommart et al., (1995) & Noda & Ohsumi, (1998). 
These authors showed that inactivation of mTOR by mutation or by treatment with rapamycin 
induced autophagy despite the presence of ample nutrients, indicating that mTOR acts to 
suppress autophagy under non-starved conditions, and as such represents a requisite molecule for 
autophagic vacuole formation. Thus, under favorable conditions, activation of mTOR promotes 
protein synthesis and inhibits protein degradation (nutrient transport turnover and autophagy). 
Upon unfavorable conditions, mTOR is inactive, leading to a reduction in protein synthesis and 
an up regulation of protein degradation. Therefore, it appears that TOR maintains a balance 
between protein synthesis and degradation such that the cell can rapidly adjust mass 
accumulation to a level appropriate to the nutrient supply (Schmelze & Hall 2000). 
 
FOXO Transcription Factors 
FOXO transcription factors are the mammalian orthologs of DAF-16, the Caenorhabditis elegans  
(C. elegans) winged helix Forkhead transcription factors (Daitoku et al., 2003). FOXO1 is 
expressed in insulin sensitive tissues such as skeletal muscle (Southgate et al., 2005), liver, and 
adipose tissue (Imae et al., 2003). In these tissues, FOXO factors play a key role in transmitting 
insulin signaling downstream of acute transforming retrovirus thymoma (Akt). In this context, 
insulin negatively regulates FOXO trans-activation of target genes, in such a way that upon 
insulin stimulation, Akt phosphorylates FOXO proteins, resulting in their cytosolic sequestration 
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(nucleic exclusion) (Rena et al., 1999; Biggs et al., 1999; Takaishi et al., 1999) and subsequent 
proteosomal degradation (Matsuzaki et al., 2003) by Skp2 (Huang et al., 2005).  
 
FOXO & mTOR 
We have recently shown (Southgate et al., 2006) that components of the mTOR pathway are 
regulated by FOXO1 (See data from Chapter 5). By using inducible, constitutively active 
FOXO1 constructs in C2C12 myotubes and transgenic animals, we have shown that FOXO 
promotes the degradation of Raptor an essential scaffold protein, that associates with mTOR to 
propagate mTOR’s growth response. Concomitantly, FOXO1 increases the protein and mRNA 
abundance of eukaryotic Initiation Factor- Binding Protein 1 (eIF4E-BP1), a molecule that 
inhibits initiation of translation by inhibiting mRNA processing. 
 
In previously published work (Southgate et al., 2005 [Data from Chapters 2, 3 and 4]), treatment 
of human primary skeletal muscle myotubes with palmitic acid (a saturated fatty acid which 
experimentally induced insulin resistance) reduced the propensity for insulin to re-localise 
FOXO1 to the cytosol resulting in the non-suppression of the FOXO target gene, PGC-1α.  
 
 In Chapter 6, a similar response in C2C12 was observed in myoblast cells, where IGF-1 (a 
growth factor with similar biological activity to insulin) failed to re-localise GFP-FOXO1 in the 
presence of Tumor Necrosis Factor-alpha (TNF-α) and the glucocorticoid dexamethasone. 
 
Lee et al., (2003) and Giannakou et al., (2004) showed in C. elegans and Drosophila respectively 
suggest that in lower organisms FoxO orthologs (Daf-16 and dFOXO respectively) play a key 
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role in longevity and lifespan extension. Taken together, the data by Lee et al., (2003), 
Giannakou et al., (2004), Klonisky et al., (1999), and those data presented in Chapter 5 and those 
data presented in Chapter 6 tentatively suggest that FoxO may well be involved in the formation 
of autophagic vacuole formation. Future work will seek to determine whether FoxO1’s role in 
lifespan extension is mediated via its propensity to reduce mTOR signaling, and thereby, induce 
autophagic vacuole formation. 
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APPENDIX 2 
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Total and phospho Akt protein abundance in murine C2C12 skeletal 
muscle myotubes stably expressing various FoxO1 constructs. Total  and 
phosphorylated (Ser 473) Akt protein abundance in C2C12 wildtype 
(pBABE), dominant negative (FoxO1-215) or constitutively active (CA-
FoxO1) myotubes treated with (+) or without (-) 4-OH TAM. No significant 
differences detected (P <0.05) compared with 0h. 
 
